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Abstract 
Introduction: Mesoporous silica nanoparticles (MSNs) are outstanding nanoplatforms for 
drug delivery. Herein, the most recent advances to turn MSN-based carriers into minimal 
side effect drug delivery agents are covered. 
Areas covered: This review summarizes the scientific advances dealing with MSNs for 
targeted and stimuli-responsive drug delivery since 2015. Delivery aspects to diseased 
tissues together with approaches to obtain smart MSNs able to respond to internal or 
external stimuli and their applications are here described. Special emphasis is done on the 
combination of two or more stimuli on the same nanoplatform and on combined drug 
therapy. 
Expert opinion: The use of MSNs in nanomedicine is a promising research field because 
they are outstanding platforms for treating different pathologies. This is possible thanks to 
their structural, chemical, physical and biological properties. However, there are certain 
issues that should be overcome to improve the suitability of MSNs for clinical applications. 
All materials must be properly characterized prior to their in vivo evaluation; furthermore, 
preclinical in vivo studies need to be standardized to demonstrate the MSNs clinical 
translation potential. 
 
Keywords: Mesoporous Silica Nanoparticles, Targeting, Stimuli-responsive Drug Delivery, 
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Article highlights  
• Mesoporous silica nanoparticles (MSNs) have evidenced to be an outstanding 
platform for the design of nanosystems able to treat several types of diseases. 
• MSNs show high versatility and multifunctionality opening the range of 
nanoparticles possibilities in biomedical applications. 
• Their stimuli-responsive and targeting properties make MSNs promising therapeutic 
nanocarriers minimizing side effects of drugs. 
• These nanosystems can be designed to tackle different situations as simultaneous 
co-administration of drugs or the combination of certain physicochemical effects 
together with conventional drugs, so therapeutic efficacy would be improved. 
 
1. Introduction 
Nowadays, mesoporous silica nanoparticles (MSNs) constitute advanced inorganic 
nanoplatforms with an enormous interest as drug delivery systems (DDS) [1]. The main 
strengths of mesoporous silica nanoparticles in comparison to others are: (1) a high drug 
loading capability due their high surface area (> 700 m2 g-1) and pore volume (> 0.6 cm3 g-
1) [2,3], (2) a tunable mesopore size (2-10 nm) and pore shape/connectivity, (3) an 
affordable chemical surface functionalization [4], (4) a controllable/tunable degradability 
under biological environments [5,6], (5) a high biocompatibility both in vitro and in vivo [7] 
and (6) a high level of clearance and excretion [8]. Besides their known possibilities as 
conventional drug delivery carriers, MSNs and related hybrid particles are suitable 
candidates for incorporating most of nanotechnological breakthroughs, as will be reviewed 
along the manuscript. In fact, mesoporous silica has gone beyond being a simple material 
for building nanoparticles, it has become a widespread material for connecting different 
units into multifunctional and degradable nanocomposites [9]. 
Figure 1 summarizes the main types of MSNs structures and their combination with some 
other inorganic nanomaterials. For instance, there are examples in which MSNs are 
coated with gold nanorods (MSN-AuNR), gold nanoparticles (MSN-AuNPs), silver 
nanoparticles (MSN-Ag) and magnetite nanocrystals (MSN-Fe3O4), whereas gold, iron 
Ac
ce
pte
d M
an
us
cri
pt
 
oxide and upconversion nanocrystals have been also employed for the preparation of 
core@shell type structures. 
Beyond those advantages, MSNs can be fabricated in a relative large-scale synthesis 
showing a great variety of morphologies and functionalities, thus widening the range of 
possibilities in biomedical applications. In general, MSNs are easily synthetized via a 
modified Stöber method which, upon the appropriate modifications, permits to prepare 
different kinds of particles with variable sizes, mesopore sizes and connectivity [10]. In this 
sense, it is possible to prepare particles with either centered radial pore arrangement 
(MSNR) with three-dimensional structure and highly accessible mesopores [11] or 2D-
hexagonal structures (honeycomb-like network) with parallel-longitudinal pores (MSNL). 
Moreover, during the nanoparticle design, the main factors that could influence into their 
biodistribution behavior should be taken into consideration (Figure 2) [12–14]. 
This manuscript arises from the need to update the state of the art in the use of MSNs and 
related nanosystems in the nanomedicine area since there has been a breakthrough in the 
last years in the versatility and multipurpose of these nanosystems [1]. Herein, we will only 
focus on the most recent advances reported for targeted and controlled release for drug 
delivery, although we are aware that this nanotechnology has clearly transcended into 
many other nanomedicine fields. 
 
2. Selective targeting 
MSNs tend to accumulate in body defense organs rich in macrophages (liver and spleen) 
leading to a poor accumulation in the target tissue as it happens with other nanoparticles 
[15]. Therefore, it is mandatory to increase the specificity towards the target tissue in order 
to enhance their therapeutic efficacy and hence to decrease their potential side effects 
[16,17]. 
In a conventional approach, nanocarriers are administered through the bloodstream and 
most of them tend to escape through aberrant neovasculature and accumulate into tumor 
areas. This is known as enhanced permeation and retention (EPR) effect and is the cause 
of the passive targeting. Once there, the active targeting based on receptor-ligand 
affinities is the responsible of the discrimination of diseased cells onto which the 
therapeutic effect would be exerted. Along this section, the most recent advances in 
targeting for MSNs will be tackled. 
 
2.1 Passive targeting 
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Passive targeting is based on the EPR effect as mentioned above. Basically, it is based on 
the size of nanoparticles and their ability to extravasate through tumor vasculature, which 
is highly imperfect and permeable. This extravasation at the tumor would lead to a 
preferential accumulation into damaged tissues. In this case, since MSNs exhibit great 
drug loading capability, it is possible to achieve high concentration of drugs into the tumor 
tissue in comparison to the free drugs. However, this accumulation will only occur if MSNs 
can prevent fast renal clearance and uptake by the reticuloendothelial system [15]. In this 
sense, the non-specific adsorption of serum proteins onto the nanoparticles is highly co-
related with their rapid clearance [15]. Different approaches to decrease the protein 
adsorption have been described based on the functionalization of the outer surfaces of 
MSNs, such as the functionalization with hydrophilic polymers as poly(ethylene glycol) 
(PEG) [18–20] or the zwitterionization of the surfaces through covalent attachment of 
functional groups with both positive and negative charges [21]. Today it is well-known that 
protein adsorption plays a pivotal role in the stealth properties [22] and affects the cell 
selectivity of active targeting of the MSNs [23]. 
In the present section the main factors that affect the biodistribution of MSNs are 
summarized. Properties such as size, shape, surface charge, and composition of the 
MSNs will influence the tissue accumulation and cellular uptake of the nanoparticles and 
will be described below [24,25]. 
 
2.1.1 Size and shape  
In general terms, it is well-established that the optimum size of nanoparticles for 
biomedical application is between 10-300 nm. [1] The lower limit is set to avoid the fast-
renal clearance while the upper limit is set to prevent embolisms due to aggregation into 
capillaries and alveoli. Numerous studies suggest that nanoparticles with a size below 100 
nm exhibit optimal levels of cell internalization.  
In addition, the shape of nanoparticles is also a key factor in both cell interaction and 
systemic biodistribution. Traditionally, spherical nanoparticles have been most employed in 
nanomedicine due to their relatively easy fabrication processes. However, non-spherical 
nanomaterials (i.e. rods, disks, cylinders and ellipsoids) show different behavior in terms of 
biocompatibility, biodistribution and clearance [25,26]. In this sense, rod-like MSNs have 
been studied to determine their destination in vivo. There was found that short-rods MSNs 
were retained by the liver, while long-rods MSNs were preferentially allocated in the 
spleen. [26]  
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In parallel, the effect of shape in the cellular uptake has been also studied, showing that 
long-rod shape displays better internalization [27]. Regarding their elimination, MSNs are 
mainly excreted by urine and faeces and, for a given diameter, the clearance is highly 
dependent on the shape. Unfortunately, there are factors beyond morphology that also 
affect the biodistribution and circulation time of MSNs, as there will be reviewed below. 
 
 
2.1.2 Surface 
Both chemical composition and surface charge play a pivotal role in the interaction with the 
physiological environment. These factors acquire great relevance in the case of MSNs 
which exhibit high surface area and pore volume. The challenges in designing MSNs are 
both to increase the blood circulation time and to enhance stability in physiological fluids in 
order to ensure their full functionality and efficacy along all their lifespan. Herein, it is also 
important to note that plasma proteins tend to be adsorbed onto MSNs throughout a non-
specific adsorption, as it has been mentioned above. This effect, called opsonization, 
generates a new surface onto such particles, denoted as protein corona. This new protein 
surface becomes then the “visible” surface of the particle and, therefore, may affect the 
targeting efficiency, biodistribution, toxicity and thus the nanosystem efficacy. In the worst-
case scenario, the protein corona would disrupt the uptake of nanoparticles and would 
trigger an immune response. Fortunately, opsonization can be avoided by creating strong 
hydration layers on the surface of MSNs. The most common strategy consists in 
decorating the nanoparticle surface with non-toxic hydrophilic polymers such as PEG in a 
process denoted as PEGylation. This process can be carried out by two different 
methodologies: covalent grafting or physical adsorption. Thus, PEGylation prevents the 
non-specific protein adsorption, which enhances the physiological stability and increases 
the blood circulation time. The stealth properties of PEGylated MSNs are strongly 
governed by the PEG size, surface chain density and conformation. It has been shown 
that molecular weights from 10,000 to 20,000 are the optimal for minimizing the non-
specific adsorption of proteins [28]. However, the range of adsorption could also depend 
on the chemical strategy used to graft PEG to the MSNs surface. The covalently 
PEGylated MSNs present greater stealthiness, achieving higher blood circulation times 
and lower protein adhesion than the physically PEGylated MSNs. 
On other hand, zwitterionization has recently appeared as a powerful alternative to 
PEGlylation. A zwitterion surface can be defined as polyampholytes with the same number 
of positive and negative charges, which ensures their electrical neutrality [29]. These 
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surfaces create a strongly fixed hydration layer forming a physical and energetic barrier 
that impedes non-specific adsorption of proteins [30]. Several strategies have been 
optimized to confer zwitterion properties to the MSNs surface. One of the most employed 
approaches is the covalent grafting with zwitterion polymers that present positive and 
negative charged groups within their backbone [31]. However, such strategy remarkably 
increases the hydrodynamic size of MSNs, which could represent a handicap for drug 
delivery applications. A possible alternative could be attaching small zwitterionic moieties 
such as 2-methacryloyloxyethyl phosphorylcholine. This approach was evaluated in a new 
multifunctional nanodevice based on polyethylenimine coated core@shell Fe3O4@MSNs. 
[32] The resulting nanodevice showed low protein adsorption values in Bovine Serum 
Albumin and Fetal Bovine Serum solutions, while allowed the co-delivery of two 
therapeutic agents, siRNA and daunorubicin. Additionally, our research group has also 
optimized a synthetic route with organosilanes  throughout a very simple methodology.[33] 
This approach consists on the direct and simultaneously grafting of two organosilanes 
exhibiting functional groups with compensated positive and negative charges onto already 
prepared MSNs. Therefore, MSNs were functionalized via simultaneous direct post-
grafting with 3-aminopropyl silanetriol and trihydroxysilylpropylmethylphosphonate, 
providing a zwitterion-like surface under physiological pH conditions. These zwitterion-like 
MSNs (MSN-Zwitter) were compared with PEGylated MSNs (MSN-PEG) using a PEG of 
similar length in terms of both non-specific protein adsorption and macrophage uptake. 
The results confirmed that both MSN-Zwitter and MSN-PEG displayed a significant 
reduction of serum protein adsorption and macrophages internalization with respect to 
unmodified MSNs. In the case of MSN-Zwitter, their reduction was up to 70-90% for 
protein adsorption and ca. 60% for macrophage uptake. Figure 3 displays a representative 
illustration showing both PEGylated and zwitterion strategies to increase the stealthy of 
MSNs.  
Besides PEG and zwitterions, an additional strategy for protecting the MSNs from the 
action of plasma proteins is the use of protocells. Briefly, protocells are lipid-coated 
mesoporous nanosystems which due to the presence of an outermost lipid layer are able 
to skip opsonization. Moreover, beyond the enhanced circulation time, those systems also 
show important advantages as their use overcomes the issues related to drug 
encapsulation, pore gating and targeting. Some differently examples of targeted protocells 
will be reviewed in the following sections. Furthermore, we recommend the review by 
Brinker and coworkers in reference [34] for the interested readers. 
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Besides the strategies aimed at reducing the interaction with serum proteins, another 
important strategy is to enhance the overall cellular uptake. This could be achieved by 
increasing the electrostatic interaction between the surface of the nanoparticle and the 
target cell membrane. Despite its non-specificity, this approach has been generally used 
by the scientific community for internalization in eukaryotic cells. Recently, internalization 
of MSNs in prokaryotic cells, such as Gram-negative bacteria, has been achieved through 
the external functionalization of MSNs with poly(propyleneimine) dendrimers of third 
generation. This nanosystem loaded with the antibiotic levofloxacin in the mesopores was 
highly effective in the elimination of Escherichia coli biofilms [35]. The decoration of MSNs 
with the polycationic dendrimers afforded high positive charge density through flexible 
macromolecules, providing the MSNs with bacterial membrane interaction capability and 
internalization thus increasing the therapeutic efficacy of the antibiotic.  
 
2.2 Active targeting 
Despite significant advances made to promote the internalization of nanoparticles into 
tumor cells, biological recognition remains as the fundamental tool for the development of 
targeted therapies. This kind of targeting requires from surface modification of 
nanoparticles with ligands able to interact with membrane receptors overexpressed in 
diseased organs, tissues and cells. This strong ligand-receptor interaction will lead to a 
specific retention able to promote the endocytosis of nanoparticles into the target cells, 
complementing the EPR effect showed by most of solid tumors. In this approach, the 
efficiency of recognition and its latter internalization depend on several parameters, such 
as the abundance of the overexpressed receptors, the ligand density attached to the 
MSNs, and more importantly, the affinity between both counterparts. The two latter 
aspects are intrinsic to the nanosystems employed, so there must be accounted during 
their design and the strategy employed to conjugate ligands into nanoparticles. Among 
those strategies, amide formation and maleimide-thiol coupling are the most recurrent 
among the wide variety of strategies [1,36]. Conventional targeting labels include small 
molecules and biomacromolecules and their fragments; however, due to their interest, 
there have been reported examples beyond those categories, as summarized on Table 1 
and Figure 4. 
 
2.2.1 Antibodies 
Antibodies (ABs) are the most efficient and specific targeting ligands known, although they 
are the most sensitive, which increases the difficulty to handle them, and attach to MSNs 
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[1]. Despite their drawbacks, their outstanding antigen-recognition capacity has seduced 
many research groups to use ABs as targeting components for raw MSNs and functional 
core@shell MSNs. To avoid the difficulty associated to their grafting, most of ABs are 
bound onto the surface of particles by electrostatic interactions or through covalent 
bonding under very mild and specific bond-forming reactions.  
Another great disadvantage associated to the use of ABs is the possible induction of 
immune responses, which can lead to complete failure of the nanocarrier. To mitigate this 
issue, it is usual to find hydrophilic moieties –mainly PEG polymers– and cross-linkers 
connecting both subunits. This strategy provides an additional immune stealth to the 
system. The nanosystems reported by Vivero-Escoto and Cai can be cited as examples of 
the conjugation of ABs and MSNs through PEG spacers. In the first case, MSNs were 
connected to the TAB-004 anti-Mucin-1 antibody throughout a 2 kDa PEG and the 
resulting system proved to be highly sensitive to Muc-1 positive human breast cancers 
[37]. In the second example, biodegradable and large-pore dendritic MSNs were 
decorated with the TRC105 Anti-Endoglin –CD105– antibody [38], enabling the detection 
of particles via positron emission tomography imaging. For complementing this strategy, in 
which the SiO2 matrix is labelled, Fortin and coworkers designed a similar approach in 
which the surface of MSNs was decorated with the Ri7 anti-mouse transferrin receptor 
antibody and a Gd-based contrast agent for magnetic resonance imaging [39]. In this case 
the transferrin antigen, located at the brain, permitted to highly accumulate and detect the 
MSNs.  
AB-coated MSNs have also proved to be highly valuable for the development of drug 
delivery agents. Along this line, there could be found a contribution by Buske and 
coworkers, who designed a system able to deliver daunorubicin to CALM-AF10 cells due 
to the presence of anti-B220 (CD45R) and anti-CD9 ABs [40]. Outstanding results 
employing ABs have also been obtained by the Vallet-Regí group with the use of a 
collagenase-based nanodriller with an anti-EGFR targeting [41]. In this system topotecan 
loaded MSNs based protocells were decorated with collagenase nanocapsules and ABs at 
their surface. The complete system proved to go across a thick collagen layer (which 
mimicked the extracellular tumor matrix) and to reach an underlying cell layer to deliver the 
loaded drug. ABs have also been employed for targeting silica nanocomposites. For 
instance, Mao and coworkers designed a system in which rod-like Bi2S3 core@shell-MSNs 
were chemically conjugated with trastuzumab [42]. The resulting system, able to attenuate 
X-rays due to the presence of a heavy cation, permitted to perform deep tissue computed 
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tomography imaging while destroying tumors thanks to the drug loaded within the 
mesopores and the photothermal capacity of the core Bi2S3. 
Besides common chemotherapeutics, there has also been reported the use of 
poly(ethyleneimine) (PEI)-coated MSNs decorated with ABs for the delivery of siRNAs. In 
this case, Yantasee and coworkers combined the trastuzumab targeting to HER2 with a 
HER2 siRNA [43], achieving a viability reduction on BT474 HER2 positive human breast 
cancer cells. Another interesting application of AB-targeted MSNs is their use as 
radiotherapy adjuvants, as reported by Tsuchimochi and coworkers. In their work, 
dendrimer coated MSNs decorated with anti-HER2 antibody were employed to selective 
internalize into SK-BR3 cells. Those cells showed increased apoptosis when X-rays were 
irradiated, suggesting a new feature for MSNs: sensitizing agent for radiotherapy [44]. 
 
2.2.2 Proteins 
Certain proteins are involved in the accelerated metabolism of cancer cells and can be 
employed to target such cells. This is the case of transferrin (Tf), involved in the 
transportation of iron into cells, and Epidermal Growth Factor (EGF), which stimulates cell 
growth and differentiation. The high demand of those proteins by cancerous tissues 
leaded to the overexpression of specific ligands, which permitted to use them as targeting 
moieties [1,36]. Although Tf has been classically employed as uptake promoter, it also has 
been described as mesopore gating component as demonstrated by Vallet-Regí and Han 
groups. In the first example, a light-cleavable photolinker was employed to connect Tf to 
MSNs  and this configuration permitted to efficiently target HT1080 cells and perform 
remote cleavage upon UV irradiation [45]. In the second example, Tf was bound to MSNs 
through an S-S bond [46], which allowed Tf disassembly under reductive conditions. This 
system was able to target HuH-7 cells and, once internalized, induce intracellular 
glutathione depletion plus doxorubicin (DOX) release, although with a limited apoptotic 
efficiency. 
In a recent example by the Vallet-Regí group MSNs decorated with Tf act as nanoplatform 
for the nucleation and immobilization of AgNPs (MSNs-Tf-AgNPs). Due to the receptor 
mediated endocytic mechanism for the internalization of the nanosystem, the transported 
AgNPs dissolve in toxic Ag+ ions during the retention time within the lysosomes, following 
the “lysosome-enhanced Trojan horse effect”. Therefore, key proteins and transcripts 
involved in cell cycle regulation, cell proliferation and DNA damage are affected, as 
demonstrated by quantitative proteomics and validated by qPCR. This nanosystem safely 
delivers AgNPs to cancer cells with a therapeutic purpose [47]. 
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In addition to Tf, other proteins have been described as targeting moieties for MSNs. This 
is the case of the lectin concanavalin A (ConA), able to recognize cell-surface glycans like 
sialic acid overexpressed in human osteosarcoma cells [48]. In one of the reported 
examples, an acid-labile moiety was employed to connect the carboxylate-capped MSNs 
with a polyacrylic acid coating layer which was further modified with the ConA. The acidic 
cleavage of the connecting unit permitted to disassemble the construct and release the 
DOX form the mesopores. Although not studied, the outstanding apoptotic efficiency of the 
complete system may be consequence of a possible combined effect of released ConA, 
which may induce an additional cell autophagy pathway in an intracellular environment 
[49]. Other strategy based on lectin proteins was reported by Martínez-Mañez and 
coworkers. In their example MSNs were bounded to Aleuria aurantia lectin throughout the 
Lewis X antigen trisaccharide [50]. This system proved to be disassembled in the 
presence of membrane’s Lewis X antigen, thus detaching the lectin gatekeeper and 
allowing the outflow of a fluorescent probe for colorectal DLD-1 adenocarcinoma cells. 
Among all the drawbacks of employing monoclonal Abs their high manufacturing costs and 
chemical sensitivity are two of the most important. Therefore, there is a growing interest in 
developing cheaper structures able to maintain the specificity of ABs, as it is the case of 
Affibodies (AfBs) and antibody single-chain variable fragments (scFv). Those are synthetic 
proteins that include the recognition regions of ABs and thus they are able to recognize 
antigens with high specificity. Those proteins have been also included in the development 
of new generation targeted devices based on MSNs. For example, Sheng and coworkers 
reported a scFv targeted system based on MSNs [51]. Their system proved high targeting 
efficiency against Ovcar5 cells, although it was not possible to determine the potential of 
such system because no drug was loaded into the MSNs. 
One of the latest emerging disciplines in nanomedicine is the study of the protein corona 
that forms the immune system onto exogenous nanoparticles, as it has been highlighted 
before. This process leads to an assimilation of the particles by the macrophages for their 
subsequent elimination. Although this process is known to be avoided when hydrophilic 
coatings –PEG or zwitterions– are present on the particles, as mentioned above, a novel 
emerging possibility has come to light. In a visionary contribution, the Ryu group designed 
a recombinant protein with two different domains: an adhesive region plus a recognition 
domain. This protein was able to bind the surface of MSNs while exposing the bioactive 
fragment, therefore generating a targeted protein corona shield that retains targeting 
specificity [52]. The authors combined glutathione-S-transferase (GST), a well-known 
fusion-tag protein bound to a HER2 AfB and the resulting GST-HER2-AfB was able to coat 
Ac
ce
pte
d M
an
us
cri
pt
 
MSNs through the GST region exposing the HER2 recognition tag which permitted to 
target the HER2-possitive SK-BR3 cells. 
 
2.2.3 Peptides 
Peptides are short amino acid sequences –less than 50– which may have similarities with 
their parent proteins. In some cases, the use of peptides has significant advantages like 
an easier synthesis and conjugation than proteins, together with a significant lower cost 
and reduced immune response. On the contrary, peptides do not have the outstanding 
antigen specificity showed by ABs; not being a limiting factor since hormones –some of 
them are peptides– show great specificity too. However, the interest of the peptides goes 
beyond the generation of targeted systems, as they also show unique properties for 
delivery and therapy [53]. Among recognition peptides, the RGD motif (Arg-Gly-Asp) is 
highly efficient to recognize αvβ3 integrins [1]. This capacity has been exploited to develop 
multifunctional peptides for the development of nanogates. One example is the system 
reported by He and coworkers, who employed a GFLGR7RGDS, cathepsin B-cleavable 
peptide sequence, to thread and release a β-cyclodextrin nanocap onto the mesopores 
[54]. Another all-purpose targeting peptidic motif is the NGR (Asn-Gly-Arg), which is able 
to target tumor neovasculature throughout the CD13 receptor. In this sense, a linear NGR 
peptide has been successfully employed for the delivery of polydopamine coated MSNs to 
glioma cells [55]. Apart from the linear configuration of peptides, it is usual to obtain better 
results with cyclic species due to their more restricted conformation. This was 
demonstrated by Kim and coworkers who were able to target CD13 receptor with a 
disulfide-bridged NGR containing peptide with a gatekeeping role [56].  
Besides general low-specific peptides, there have been reported other sequences with 
high specificity towards receptors unique to certain cell lines. This are the cases of the 
Interleukin targeting peptide IL-13 (VDKLLLHLKKLFREGQFNRNFESIIICRDRTC), which 
has been employed to target gliomas in mice [57]; the CDX (FKESWREARGTRIERG) 
peptide with affinity for the nicotine-acetylcholine receptors present in brain [58]; the 
NAPAmide (Ac-NIe-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH2), an analog of the α-melanocyte 
stimulating hormone with great specificity towards malignant melanomas [59]; the Bld-1 
(CSNRDARRC) peptide against cancerous bladder cell lines [60]; the cyclic A6 
(CKPSSPPEECW) peptide able to achieve pore gating and target breast cell lines [61] and 
the tLyp-1 peptide (CGNKRTRGC) able to address neurophilin receptor present in many 
endothelial cells [62]. All those targeting peptides are summarized on Table 1. 
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As already reviewed, peptide targeting can be very a powerful tool to target nanocarriers 
to certain cells; however, the possibilities of peptides go beyond cell discrimination. For 
example the transactivator of transcription (TAT, GRKKRRQRRRPQ) peptide is known to 
induce particle translocation towards the nuclear membrane thanks to the importin 
transporters [63]. Apart from recognition by affinity, there are certain peptides capable of 
modifying the interaction between cells and drug delivery agents. One possibility is the 
functionalization of MSNs with peptides that may promote internalization [64,65]. Such is 
the case of polylysine, KALA (WEAKLAKALAKALAKHLAKALAKALKA) and fusogenic 
peptides which due to their cationic nature are able to electrostatically bind biological 
membranes and induce cellular uptake. Polylysine was successfully employed by Bravo et 
al. to create an enzyme-sensitive coating layer onto MSNs with favored uptake due to the 
cationic nature. This system was employed to internalize MSNs on HeLa cells and deliver 
the C9h therapeutic peptide (YVETLDDIFEQWAHSEDLK) known for activating the 
caspase-9 proapoptotic pathway [66]. For recent reviews dealing with the use of peptides 
as stimuli-responsive agents for controlled drug release in MSNs, please check reference 
[53]; and for an exhaustive review on cell-penetrating peptides, we recommend reference 
[67]. 
In addition to all the targeting features showed by peptides, there have also been reported 
some examples of double function peptides. This is the case of the osteogenic induction 
generated by dexamethasone (DEX)-loaded and peptide targeted MSNs reported by He 
[68]. In this model, a single peptide (KIPKASSVPTELSAISTLYL) was able to target the 
bone morphogenetic protein-2 (BMP-2) located in bone mesenchymal stem cells and once 
there, helped by the DEX release, induces the differentiation of stem cells towards 
osteoclasts and promote bone mineralization. 
 
2.2.4 Aptamers 
Aptamers are a special class of nucleic acids that have been evolved and selected to have 
high affinity for a particular template compound used for their synthesis. Among their 
advantages, they show (1) high affinity and specificity for their targets, (2) low complexity 
and relatively small size, (3) a facile synthesis and modification and (4) much lower 
immunogenicity than ABs. Besides, it is also remarkable that aptamers show great 
structural flexibility and thermal stability, which allow them to adapt to hidden epitopes and 
recover their active structure after thermal treatments. All those features turn aptamers into 
highly valuable components to develop gated and targeted nanosystems. For a recent 
review on the use of DNA and aptamers together with MSNs, please check reference [69]; 
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and for an excellent up to date review on aptamer-guided nanomedicines for anticancer 
drug delivery, please check reference [70]. 
Regarding their use as targeting agents, there have been reported the use of MSNs in 
combination with nucleolin aptamers (NCL/AS1411) to simultaneous deliver anti-miR-155 
and 5-fluorouracil (5FU) to SW480 colorectal cancer cells [71] or DOX to NCL-positive 
MCF-7 cells [72]. Similarly, SK-BR3 HER2 positive cells were satisfactory targeted with 
HB5 aptamer modified mesoporous silica–carbon nanoparticles [73]. Another very 
common target for aptamers is the epithelial cell adhesion molecule (EpCAM) which is 
involved in several cell signaling pathways, migration, proliferation and differentiation of 
epithelial-derived neoplasms among others. Towards this target Alibolandi and coworkers 
delivered 5FU to HepG2 using RNA aptamer [74] while Li and Jia’s groups delivered DM1 
to SW480 [75] and DOX to SW620 colorectal cell lines [76], respectively, employing a 
DNA-based aptamer. Other recent examples with aptamers targeting common receptors 
such as mucin 1 glycoprotein [77] or CD105 [78], could be also found in the literature. 
In addition to single-strands targeting aptamers, they have been also tuned to obtain pore-
gating properties. To do so, two possibilities arise: thermal dehybridation of a double 
strand or chemical displacement. An example of the former can be found in the 
contribution by Lin, who employed NCL as meltable nanogate [79], while for the later 
approach please refer to reference [69]. 
 
2.2.5 Saccharides 
Polysaccharides are widely employed as hydrophilic and biodegradable coatings for 
MSNs. The most extensively used polysaccharides are: chitosan, a linear polysaccharide 
composed of β-(1–4) linked D-glucosamine units; dextran, a branched saccharide based 
on α-1,6 and α-1,4-glucosidic linkages and hyaluronic acid (HA), a linear polymer 
consisting of D-glucuronic acid and N-acetyl-D-glucosamine linked via alternating β-(1-4) 
and β-(1-3) glycosidic bonds. Among them, HA has been widely employed for its 
interaction with the CD44 and CD168 receptors which are involved in many types of 
cancer. For example, Cai and coworkers designed a pH sensitive system by conjugating 
the HA to Hollow MSNs (HMSNs) through cleavable hydrazine bonds [80]. The system 
proved to internalize into HepG2 cell lines for DOX delivery. Similarly, Zeng and coworkers 
reported a parallel system employing a dithiol redox-cleavable linker [81], obtaining high 
internalization rates on HEK-293 cells. Both examples, in which HA performs a double 
role, show promising results in vivo since tumor growth was arrested. In addition, HA has 
been also used for its targeting ability. In an example by Glackin, MSNs were modified to 
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accomplish codelivery of cisplatin and siRNA [82]. In this system, the gatekeeper role was 
assigned to a polyethyleneimine mesh onto which the siRNA was adsorbed. The latter 
grafting of HA was accomplished by EDC-NHS coupling reaction, showing great 
therapeutic efficiency in vivo. However, it must be considered that the HA is a polymer and 
therefore can present a great variety of molecular weights. In addition, its structure 
presents both amino and carboxylic groups in stoichiometric proportion; so, the linkage of 
HA towards MSNs could be an important parameter. Along this line, Arpicco and 
coworkers made a systematic study on both aspects [83], finding that higher molecular 
weight HA (200 kDa) covalently bound in one-pot onto MSNs provided better targeting 
capabilities due to a lower self-condensation reaction rate. 
2.2.6 Small molecules 
The use of small molecules for targeting purposes is gaining attention because of its 
simplicity and low cost. Among those reported for targeting, a classification depending of 
their natural –vitamins– or synthetic source can be made. The use of vitamins and related 
compounds has become one of the most successful targeting strategies, as typically 
cancerous cells show an up-regulated uptake to satisfy their accelerated metabolism. 
However, not all vitamins are suitable candidates for these purposes since fat-soluble 
vitamins which need the aid of transporters or those with high structural complexity do not 
perform adequately. 
The most used targeting element is folic acid (FA, vitamin B9), which show a well-known 
reactivity that permits its incorporation in highly complex systems like nanogates. For 
example, Cai reported the use of FA to modify a pH-sensitive In+3-containing fluorescent 
chelate [84], while Qi and Wang reported two redox-sensitive models, based on FA-tagged 
cyclodextrins [85] and FA-modified dithiol-containing chitosan copolymer [86], respectively. 
Such is the relevance of FA that it is also employed as a reference targeting ligand, being 
an example the study that compared the drug delivery properties of two different 
mesostructures such as MCM-41 vs KCC-1 [87]. Another important vitamin employed as 
targeting label is biotin (vitamin B7 or H), whose relevance is also based on its simplicity 
and ease functionalization. Like FA, biotin has been employed to target MSNs-based 
nanosystems containing polymeric coatings [88], AuNPs caps [89], lipid bilayers [90] or 
surface-loaded prodrugs [91]. Another interesting vitamin for developing targeted 
examples is cyanocobalamine (vitamin B12), which has been elegantly coordinated to 
cisplatin-functionalized MSNs by Leeladee and coworkers [92] to obtain a MSN-based 
system with great potential for drug co-delivery. 
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Apart from vitamins, synthetic small molecules have been also successfully employed for 
the selective targeting of cancer cell populations. For example, phenyl boronic acid has 
been employed as a targeting element in protein capped MSNs. It is worth to note in this 
example the role of the connecting peptide R9PVGLIG, which is cleaved in the presence of 
the metalloproteinase-2 protein, releasing the protein cap and exposing a polyarginine 
sequence that favors the internalization [93]. Other interesting molecules are those derived 
from substituted triphenylphosphonium (TPP) [94,95] and guanidinium [96] cations. Those, 
apart from showing a facilitated non-specific uptake due to their positive charge, have also 
proven the ability to target mitochondria. This is of interest because any alteration may 
serve to disrupt the metabolism of cell and induce apoptosis. Moreover, guanidine 
derivatives have also additional recognition features, as demonstrated by Vallet-Regí. For 
example, 3 and 4-aminobenzylguanidine analogs have proved to efficiently target 
neuroblastoma cells due to their structural similarity with norepinephrine, whose 
transporter is highly overexpressed in such type of cancer [97,98]. 
 
2.2.7 Double targeting 
This new strategy is recently becoming of interest for many research groups. In this 
approach several targeting elements are combined into a single entity, providing 
complementary recognition capabilities to the system. This methodology has been 
explored with small molecules and peptides, which do not have complex reactivity. 
Pioneering examples, already reviewed by us [99], were based on random 
functionalization of MSNs with peptide combinations: RGD-TAT [100] and RGD-IL-13 [101] 
for targeting HeLa and C6 plus HUVEC cancer cell lines, respectively. Those combinations 
mimicked the pattern of receptors present on the membranes and hence improved 
recognition and uptake. 
However, depending on the capacities that are desired on the nanocarrier, there are other 
dual targeting strategies: vascular-to-cell and cell-to-organelle targeting. In this way, the 
pioneering example on MSNs was developed employing FA plus DEX as mitochondrial 
targeting [102]. In this system a random surface functionalization permitted to enter 
cancerous cells due to the presence of FA while once internalized DEX delivered the 
system into the mitochondrial area [103]. This intracellular delivery demonstrated to 
effectively disrupt the mitochondrial activity increasing apoptosis. As already mentioned, 
TPP cations are also known to produce such effect, fact that was profited by Vallet-Regí 
and coworkers to develop two possible approaches for cell to organelle delivery. The two 
systems based on an asymmetric distribution of FA and TPP onto Janus-MSNs [104] and 
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on an engineered (internal-external) ligand disposition of TPP and biotin [105] showed 
enhanced uptake and thus increased delivery of drugs. Besides the use of MSNs, double 
targeting has been also bloomed employing other nanosystems. For an interesting review 
focused on the possibilities of double targeting, please check reference [106]. 
 
2.2.8 Biological membranes in targeting 
As reviewed above, there are many compounds able to interact with biological membranes 
and cancer cells and promote a preferential uptake. However, this recognition also occurs 
between different types of cells such as blood, immune and mesenchymal stem cells. The 
particularity of these last cells is that they have tumor-tropic properties, which makes them 
interesting for developing bioactive coatings. In the case of stem cells, the targeting 
capacity was demonstrated employing upconversion (UCN) core@shell-MSNs protocells 
for photodynamic therapy (PDT) [107]. In the same way, red blood cells’ membranes were 
also employed for cloaking effect, obtaining again outstanding results enabled only by the 
effect of passive targeting [108]. 
 
3. Stimuli-responsive MSNs 
Among the three major objectives of nanomedicines - (1) trap and protect a great amount 
of therapeutic agents; (2) carry them to the specific site of the disease avoiding any 
leakage; and (3) release on-demand high local concentrations of therapeutic agents - the 
third objective of any nanomedicine should be releasing high local concentrations of 
therapeutic agents on-demand. In this sense, keeping control on the therapeutics release 
is a desirable feature so premature release can be avoided. This might be of great interest 
when the employed therapeutic might be a cytotoxic drug, so side effects on healthy 
tissues would be avoided. 
Stimuli responsive behavior is of particular interest on MSNs, because these nanocarriers 
present open porosity, so it is relatively easy to introduce therapeutic agents into their 
network of cavities. However, it might be also relatively easy for those molecules to diffuse 
out [109]. Therefore, it is necessary to design strategies to cap the pore entrances to avoid 
premature release of the cargo. Although mesoporous matrices present pores large 
enough that might be capable of hosting many different types of molecules, those pores 
are small enough to cap them with large molecules. Those caps grafted at the pore 
entrances should respond to the application of certain stimuli, so the cargo could be 
released. Recently, Zink and co-workers have divided the mesopore capping strategies 
into three groups: (1) Reusable caps, that are based on a bulky capping molecule able to 
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bind reversibly; (2) Completely reversible caps, that work on the principle of reversal of 
affinity of a macromolecule; and (3) Irreversible caps, that are based on a chemical bond 
cleavage of the capping macromolecule, which leads to the permanent separation from 
the host nanoparticle [110]. The last group includes a popular approach that consist on 
covering the external surface of the MSN with a cleavable shell that upon the application 
of the appropriate stimulus would detach from the nanoparticle triggering the cargo 
release. 
In this section, we will focus on MSNs based DDS that are capable of releasing their 
cargos in response to the presence of several stimuli. Different endogenous (pH, redox, 
enzymes and small molecules) and exogenous (light, magnetic field, temperature and 
ultrasound) stimuli have been explored to trigger drug release (Figure 5 and Table 2). Most 
of single stimuli-responsive nanosystems are easily affected by different external factors 
and may produce side effects or low release problems. In this regard, multi-stimuli 
responsive DDS have been recently developed to solve these problems. 
 
3.1. Internal stimuli-responsive MSNs 
The variations in metabolic and biochemical processes involved in pathologies such as 
cancer or inflammation diseases can be used for the design of drug delivery nanocarriers 
sensitive to endogenous stimuli. The physiological and biochemical differences between 
normal and pathological conditions (e.g., microenvironment in tumors and inflammation 
sites) are exploited since the responsive nanosystems do not require external mediation to 
trigger drug release and therefore are not invasive. In this section, we focus on the design 
of MSNs that respond to internal stimuli as pH levels and redox potential variations and 
deregulations of different enzymes or small molecules (Figure 5). 
 
3.1.1. pH 
Among the internal stimuli, pH is one of the most employed in the literature, especially 
associated with drug release for treatment in oncology or inflammation [1,106]. These 
pathologies show a significant variation of pH values over time. Tumors exhibit lower pH 
environments (6-7) compared with normal tissues (7.4), especially in intracellular 
endosomes (5) and lysosomes (< 5), and in inflamed tissues the pH can reach values of 
5.5 [1,111]. In this context, the use of pH-sensitive gatekeepers as pore blockers is an 
interesting approach to control drug release in response to the changes of pH values, 
especially in cancer. In the past, the triggered release of anti-tumor drugs from 
mesoporous channels has mainly been studied by using polyelectrolytes, supramolecular 
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nanovalves, pH sensitive polymers such as poly(4-vinylpyridine), poly(styrene sulfonate) or 
chitosan, pH-sensitive linkers (hydrazine, acetals), and acid-decomposable inorganic 
materials, together with others [1]. 
An alternative strategy is to use pH-sensitive linkers to directly graft the cytotoxic drug on 
the MSN surface [1]. In this context, different types of labile acid cleavage site 
functionalization can be used. Chen et al. developed a new pH-responsive drug delivery 
carrier by capping MSNs with functional peptide-coated gold nanoparticles [112], first 
functionalized with acid-labile α-amide-β-carboxyl groups and decorated with oligo-lysine-
containing peptide. The resulting hybrid delivery system exhibited pH triggered drug 
release and the incorporation of RGD peptide facilitates targeting delivery to αvβ3 integrin 
overexpressed in cancer U87 MG cells (human glioblastoma cells). This hybrid nanocarrier 
was successfully internalized by these tumor cells and when it was loaded with DOX 
showed a dramatically decreased (ca. 60%) in tumor cell viability. Martínez-Carmona et al. 
developed a novel multifunctional nanocarrier based on DOX-loaded MSNs as 
nanoplatforms for the assembly of different building blocks to increase antitumor 
effectiveness and decreases toxicity in normal cells: a polyacrylic acid capping layer 
grafted to MSNs via an acid-cleavable acetal linker, as pH-responsive drug delivery ability, 
and ConA, as a targeting ligand to a cell-surface glycans sialic acids overexpressed in 
tumor cells [48]. This nanocarrier showed a higher internalization rate in human 
osteosarcoma cells (HOS), and a small DOX loading (2.5 mg mL-1) induced 95% of tumor 
cell death in 48 h of cell culture, 8-fold higher than that caused by the free drug. Over the 
past few years, poly(glycerol methacrylate)s (pGOHMAs) have emerged as an efficient 
alternative to classical polymers. In a study by Yan et al. the effect of anti-tumor drug 
camptothecin (CPT) bound to MSNs with acid-cleavable silyl ether bonds to develop a 
hybrid CPT-MSN nanomedicine was evaluated [113]. Only under extracellular pH 
conditions of tumor issues (pH 6.8) the drug was partially released from the MSNs when 
the acid-labile silyl ether bonds were degraded. The rate of release was controlled by 
changing the steric bulks of the substituents of the silicon atom, at pH 4. This DDS had a 
similar efficiency as CPT free at 0.5 and 1.0 μg mL-1 with an inhibition of 40% of tumor 
HeLa cell growth. 
Regarding to host-guest interactions, in a study by Moorthy et al. MSNs were covered with 
tetrathio-maleimide as capping units and were functionalized with melamine groups 
(nitrogen-rich organic base) onto the surface by host-guest chemistry via multipoint 
hydrogen bonding interactions for pH-responsive in human breast MDA-MB-231 cancer 
cells. The nanosystem showed intracellular uptake efficiency, protecting the loaded cargo 
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molecule (rhodamine B) inside the pores and preventing its premature release [114]. Li et 
al. reported a biocompatible layer-by-layer (LbL) coated MSNs, designed to release 
encapsulated DOX by changing the pH [115]. MSNs coated with LbL blocks were 
prepared by supramolecular self-assembly, based on the non-covalent bonding 
host−guest interactions between bis-aminated PGOHMAs and cucurbit[7]uril (CB[7]), 
where CB[7] serves as a molecular bridge holding two different bis-aminated polymeric 
layers together. These MSNs successfully released DOX by lowering the pH in MDA-MB-
231 cells, decreasing the cell viability. In vivo, DOX-loaded LbL-MSNs decreased ca. 63% 
of tumor size on a BALB/c nude mice model induced by HeLa cancer cells. 
In the other hand, Hakeem et al. studied the use of polyaspartic acid (PAsA)-anchored 
MSNs as a gatekeeper via amide linkage, providing a positive charge to MSNs, which 
contributes to effective cellular uptake by HepG2 cells [116]. In vitro release results 
indicated enhanced DOX release from DOX-loaded PAsA-anchored MSNs under 
endosomal and lysosomal acidic pH condition and translocation to the nucleus to increase 
cytotoxicity in HepG2 cells. 
As we previous mentioned, there are many polymeric systems with acid-sensitive bonds 
[1]. The so-called Self Immolative Polymers (SIPs) are materials that disassemble from 
head-to-tail when a specific functional group is cleaved from the polymer in response to 
certain stimuli. In this regard, Gisbert et al. evaluated a linear SIP to cover the pore in 
MSNs in a single functional responsive nanocarrier, avoiding premature release of the 
cargo. This nanosystem showed a high loading capacity and the responsiveness of pH-
sensitive SIPs to control the release. Polyurethane backbone with a t-butyloxycarbonyl 
protecting group on the terminal amine acted as a trigger [117]. The carbamate linkage of 
the trigger was the cleavage when the pH diminished, starting the sequential 1-6 
elimination and decarboxylation reactions yielding CO2 and the initial monomer. MSNs 
capped with the acid responsive SIPs were selective internalized by human prostate 
adenocarcinoma LNCaP cells, indicating that SIPs could be interesting for future 
applications in nanomedicine. 
Of special interest is the study by Pan et al. about a novel pH-responsive drug delivery 
platform based on a zeolite imidazole framework-8 (ZIF-8) film with a few nanometer 
thickness synthesized in situ on the surface of carboxylate functionalized MSNs [118]. This 
approach showed a pore blocking and efficient loading of small interfering RNAs. In this 
study the author chose a Bcl-2 siRNA, because this gene is implicated in the activation of 
the cellular antiapoptotic defense. The positively charged of ZIF-8 film increased the 
siRNA loaded into MSN and the cellular internalization and endo-lysosome escape, 
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protecting from nuclease degradation. In addition, the ZIF-8 film was degraded in the 
acidic endosome and induced the intracellular release of siRNAs and DOX, increasing 
their efficacy in MCF-7/ADR and SKOV-3/ADR cancer cells. This technology is a 
promising strategy for pH-triggered, combining stimuli-responsive delivery of siRNAs and 
chemotherapeutic agents with an increased therapy efficacy. 
 
3.1.2. Redox 
The differences in redox potential between extracellular and intracellular environments and 
between normal and tumor tissues, with a dissonant production of reduce glutathione 
(GSH) or reactive oxygen species (ROS), allow the development and use of redox-
responsive drug release systems for biomedical applications [1,111]. 
Among all the possibilities, surface modifications based on disulfide bonds with bulk 
gatekeepers are widely used. The cleavage of the disulfide bonds results in the 
detachment of entire polymer from MSNs. In a study developed by Sha et al. a novel 
method was used to successfully coat Pluronic P123 (PSMSNs) and octadecyl chain-
modified (PMSNs) into MNSs [119]. Compared with the PMSNs, the PSMSNs displayed a 
redox-responsive drug release both in vial and in mouse 4T1 breast tumor cells, due to the 
cleavage of the disulfide bond by highly concentrated GSH, under which circumstance the 
hydrophobic chain was set free, P123 lost support and detached from the surface of the 
MSNs. The accumulation of P123 in the tumor in an in vivo model was enhanced by the 
EPR effect after coating the MSNs with P123 compared with the free P123. Redox-
responsive nanocarriers for anticancer drug and gene co-delivery are promising 
synergistic strategy in cancer therapy, delivering high local concentration of drugs without 
premature release. Lin et al. developed a redox stimuli-responsive and synergistic co-
delivery nanosystem for DOX and p53 gene based on MSNs and dendronized chitosan 
derivatives (CP) as a gatekeeper to control release [120]. The loaded DOX was control 
released under higher GSH situation in HeLa tumor cells, and the nanosystem showed 
enhanced p53 gene delivery inducing an increase in p53 protein expression in these cells. 
DOX and p53 co-delivered from this MSN nanocarrier induced a significant cytotoxicity in 
tumor cells, higher than p53 or DOX used singly, resulting in a synergistic dual delivery 
system promising for cancer therapeutic approach. On the other hand, polycations in the 
pores of MSNs allows load and controlled release of therapeutic siRNAs. Prabhakar et al. 
studied the combination of MSNs with PEI tethered with redox-sensitive linkers that allows 
a high siRNA concentration (120 mg g−1) [121]. This nanocarrier loaded with a cell-killing 
siRNA was efficiently internalized by MDA-MB-231 tumor cells, escaping from endosome, 
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releasing the functional siRNA intracellularly and showing a promising long-term gene 
knockdown efficiency. 
In another study Lee et al. designed an all-peptide gatekeeper with on-off gatekeeping 
capability through stimulus responsive conformational conversion and the steric bulkiness 
of the tryptophan unit of the zinc finger domain peptide (CXXC) [122]. Due to a reduction 
of the disulfide bond by GSH, the peptide conformation was converted to a random 
structure, which opened the mesopore releasing DOX loaded into MSNs in a controlled 
manner. This nanosystem was efficiently internalized and specifically induced a higher 
cytotoxicity in A549 human lung cancer cells. 
In a study by Cheng et al. a ROS-responsive free-blockage controlled release nanosystem 
was explored, controlling the wetting behavior of the internal surface of nanopores on 
MSNs by modification with a hydrophobic phenyl sulfide [123]. Under the stimulation of 
ROS, the sulfide groups are oxidized triggering the release of DOX loaded into MSNs 
specifically in MCF-7/ADR tumor cells. This effect is possible due to the shift of nanopore 
environment from hydrophobic to hydrophilic, inducing a higher rate of cytotoxicity in these 
cells. 
 
3.1.3. Enzymes 
Cancer and other pathologies course with an overexpression and deregulations of several 
enzymes, which can be also used as release triggers, including esterases, matrix 
metalloproteinases (MMPs) and others [1]. MMPs are a family of proteins with protease 
activity, which are overexpressed in the tumor’s environment, in particular of liver and 
colon tumors. Liu et al. have described a MMPs responsive, MSN-based for DOX by using 
bovine serum albumin as end-cap, peptide substrate of MMPs as intermediate linker and 
lactobionic acid as targeting moiety [124]. The authors induced tumors by injecting HepG2 
cells into nude mice. This nanocarrier was successfully accumulated at liver tumor site, 
delivering DOX to tumor tissue triggered by MMPs, for tumor growth decreased. In 
addition, Cheng et al. designed a tumor-targeted and enzyme-induced DOX delivery 
system, with cleavable rotaxanes anchored onto the orifices of MSNs as gatekeepers and 
azido-GFLGR7RGDS (multifunctional peptide with tumor-targeting, membrane-penetrating 
and cathepsin B-responsive functions) to stabilize it [54]. This novel nanocarrier was 
efficient internalized by HeLa cells thanks to integrins-mediated targeting and released 
DOX via enzymatic digestion of GFLG peptide due to cathepsin B overexpressed in late 
endosomes and lysosomes of tumor cells. 
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Baeza et al. studied an interesting approach consisting in the incorporation of enzymes in 
the nanocarrier itself [125], able to transport a non-toxic prodrug (indol-3-acetic acid, a 
plant growth hormone) and the enzyme (horseradish peroxidase) responsible for its 
conversion into cytotoxic compounds coated with a protective polymeric shell grafted to 
MSNs. This nanodevice was effective internalized by neuroblastoma (NB1691-luc) and 
leukemia (NALM6) cells and generated enough cytotoxic substances to specifically kill 
these cells, decreasing the side effects of current antitumor drugs. Once the nanosystems 
were internalized by tumor cells, intracellular enzymes degrade the protective polymeric 
shell and permit horseradish peroxidase to oxidize indol-3-acetic acid molecules, 
producing ROS that decreased human cancer cells viability. 
 
 
3.1.4. Small molecules 
As in the case of enzymes, the identification of some chemical species that are produced 
or accumulated in an unbalanced way due to a pathology can lead to their use as 
chemical signals to trigger the drug release by opening of the mesopores blockers or 
nanogates. A variety of small molecules, such as glucose, ROS or adenosine triphosphate 
(ATP), have been used as key molecules or trigger events. 
 
3.1.4.1 Glucose 
Glucose-sensitive MSNs may provide self-regulated insulin delivery systems for diabetes 
treatment in which a certain amount of insulin can be released in response to the blood 
glucose concentration. In a pioneering article from the group of Lin, gluconic acid-modified 
insulin proteins were immobilized on the exterior surface of boronic acid-functionalized 
MSNs, being as well caps to encapsulate cyclic adenosine monophosphate molecules 
inside the mesopores. The release of both gluconic acid-modified insulin and cyclic 
adenosine monophosphate was triggered by the introduction of saccharides such as 
glucose, being a double release system in which the decrease of insulin level could be 
overcome by delivering the cell-membrane-impermeable cyclic adenosine monophosphate 
into the cytosol to stimulate insulin secretion from pancreas beta cells [126]. 
In a similar fashion, a novel multifunctional MSNs system with integrated glucose-
responsive double-drugs release and fluorescent real-time monitoring capabilities of the 
hypoglycemic drugs released has been recently developed. This system takes advantage 
of the principle of competitive binding between a hydrophobic boronic acid, glucose, and a 
fluorescent reporter molecule such as alizarin. This competitive binding mechanism not 
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only ensures the response to glucose but also can cause the change of the fluorescence 
signal simultaneously. The signal reporter, alizarin complexone, is attached onto the 
surface of MSNs and then, the gluconated insulin, which acts as hypoglycemic drug and 
capping agent, is immobilized on MSN via a benzene-1,4-diboronic acid mediated 
esterification reaction. In the absence of glucose, the sandwich-type boronate ester 
structure formed by the diboronic acid binding to the diols of alizarin complexone and 
gluconated insulin simultaneously remains intact, leading to the blockage of mesopores. 
Furthermore, the boronate ester displays an emission peak at 570 nm under excitation of 
460 nm light at this stage. When glucose is present, it binds the diboronic acid 
competitively and cause the dissociation of boronate ester. As a result, gluconated insulin 
is departed from the alizarin complexone functionalized MSNs, triggering the opening of 
mesopores, the disappearance of fluorescence and the diffusion of gluconated insulin and 
rosiglitazone maleate as the hypoglycemic drug loaded into the MSNs [127]. 
Another approach has been reported for insulin delivery in which glucose is not the trigger 
molecule, though it is necessary for the delivery event. The enzyme glucose oxidase 
(GOx) and insulin were encapsulated into MSNs and the insulin retention was achieved 
through the host-guest complex formed between 4-(imidazoyl carbamate)phenylboronic 
acid pinacol ester on the surface of the MSNs and α-cyclodextrin (α-CD). GOx in MSN 
could convert glucose to gluconic acid and generate H2O2 as byproduct and trigger event. 
The phenylboronic ester on the surface of MSNs could be oxidized in the presence of 
H2O2 that resulted in the destructive disassemble of the host-guest complex, leading to the 
subsequent release of the preloaded insulin. The hypoglycemic effect was in vivo 
investigated after transdermal administration to diabetic rats using a novel microneedles 
delivery device, which integrates the MSNs loaded with insulin and glucose-mediated 
responsive to H2O2 [128]. 
 
3.1.4.2. ROS and H2O2 
Excessive amount of various ROS, such as superoxide (O2−), hydroxyl radical (•OH), 
hypochlorite ion (OCl−), hydrogen peroxide (H2O2) and singlet oxygen (1O2), are produced 
at the site of inflammation of some diseases including many types of tumors in cancer, 
infected tissues, injuries and neurodegenerative diseases [129–131]. Therefore, as we 
have mentioned for the redox stimulus, ROS pathological signals are being exploited to 
design oxidative triggered drug release MSNs. Typically, boronic ester and thioketal are 
emerging oxidation-responsive functional groups which can be readily cleaved by H2O2 in 
oxidative stressed microenvironments. 
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Sometimes the exposure of the capped MSNs nanocarrier to the disease inherent 
concentration of H2O2 fails to open the ROS-sensitive nanogates of the MSNs and 
therefore some strategies have been developed to overcome insufficient ROS 
concentration. A metal mediated drug delivery MSNs system responsive to hydroxyl 
radicals is based on the introduction of the Fenton reaction (Fe2+ + H2O2  Fe3+ + •OH + 
OH−) into the nanosystem. The authors used thiol stabilized ZnS quantum dots (QDs) as 
nanocaps to regulate the release of the anticancer drug from MSNs in response to 
oxidative environment. Addition of catalytic amounts of divalent iron readily unseals the 
nanochannels at considerably low H2O2 concentrations due to the generation of highly 
reactive hydroxyl radicals. The exposure to •OH resulted in the oxidation of thiol groups, 
thus destabilizing the ZnS nanolids to open the mesopores and release the drug [132]. 
Another example is based on a positive feedback strategy utilized to amplify the 
concentration of intracellular ROS. In this case, the MSNs are loaded with the anticancer 
drug DOX and a ROS producing agent, α-tocopheryl succinate (α-TOS). The gatekeeper 
β-CD is anchored on the surface of MSNs through the ROS-cleavable thioketal linker for 
ROS-triggered drug release. Once the nanosystem has been taken up by tumor cells, but 
at the very beginning, only limited pores are open because of the existent but insufficient 
intracellular ROS, resulting in the simultaneous though restricted release of loaded DOX 
and α-TOS. Then, released α-TOS interacts with mitochondria to generate additional 
ROS. In other words, the intracellular ROS would be self-regenerated and amplified, which 
in turn facilitates the cutting of the thioketal linkage to remove the gatekeeper and led to 
more release of α-TOS as well as the self-accelerating release of toxic DOX from the 
MSNs [133]. 
A ROS-activated yolk-shell nanoplatform has been designed for the simultaneous delivery 
of protein and small-molecule anticancer drugs. The cytochrome c (Cyt c)/DOX dual 
therapy is achieved by immobilizing Cyt c onto the surface of yolk-shell MSNs (YMSNs) 
via H2O2-liable boronic ester bonds and further modifying the nanocarrier with lactic acid 
units to confer as well selective tumor targeting against liver cancer cells. The bioactivity of 
Cyt c is temporarily shielded by the boronic ester linkages and readily restored in the 
H2O2-rich tumor intracellular environment, therefore protecting the protein drug from 
biodegradation. Moreover, the immobilized Cyt c moieties effectively cap the 
nanochannels of YMSNs to avoid the premature delivery of DOX [134]. 
With the goal of treating neurological diseases caused by oxidative stress, a MSNs system 
able to actively cross the blood-brain barrier (BBB) and release an antioxidant drug upon 
ROS stimulation has been described. The MSNs are loaded with resveratrol and then 
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coated with polylactic acid as gatekeeper followed by conjugation with a ligand peptide of 
low-density lipoprotein receptor to enhance the MSNs transcytosis across the BBB. The in 
vitro model of BBB/inflammation was established with a co-culture of rat brain 
microvascular endothelial cells (RBECs) and microglia cells using Transwell chambers. 
The RBECs on the top well can form tight junctions and create a transport barrier 
mimicking the BBB, while microglia on the bottom wells could be stimulated exogenously 
to produce abundant superoxide or nitric oxide. The conjugation of the ligand peptides 
markedly enhanced the migration of MSNs across the RBECs monolayer via receptor 
mediated transcytosis. Finally, the polylactic acid coating was degraded by the high 
concentration of ROS produced by microglia and resveratrol was subsequently released to 
reduce inflammation [135]. 
3.1.4.3. ATP 
ATP, which is the molecular unit of currency for intracellular energy transfer, is also 
considered among the endogenous stimulus based on key small biomolecules. The ATP 
levels within the intracellular cytosol are higher than in the extracellular environment 
[136,137], therefore, the ATP concentration may trigger the release of drugs in the cytosol. 
ATP is also found to be upregulated in cancerous tissues and in processes such as 
chemoresitance and uncontrolled tumor growth, hence making possible to exploit 
differences between normal and cancer cells [138,139]. Competitive binding or 
displacement reactions use to be the mechanism that takes place to unblock the 
mesopores under the stimulus of ATP concentration. 
An ATP-responsive nanocarrier for intracellular drug delivery and real-time monitoring of 
drug release through fluorescence resonance energy transfer has been fabricated by 
using graphene quantum dots (GQDs, the acceptor) as caps onto fluorescent MSNs (the 
donor) via an ATP aptamer. Under extracellular conditions, the fluorescence of MSNs 
remains in the “off” state in the low ATP level which is unable to trigger the release of drug. 
Once specifically recognized and internalized into the target tumor cells, in the ATP-rich 
cytoplasm, the ATP aptamer switches its conformation causing the shedding of the GQDs 
from the nanocarriers. The loaded drugs are then released and, simultaneously, the 
fluorescence of MSNs turns “on” along with the dissociation of GQDs, which allows 
monitoring drug release from the pores in real-time [140]. 
The same concept, intracellular and real-time monitoring drug release in response to ATP, 
has been achieved in a core@shell nanosystem that consists of an upconversion 
nanoparticles (UCNPs) core and an MSN shell (UCNPs@MSNs). The biogate for ATP-
responsive drug release comprises of a dipicolylamine-zinc analogue (TDPA-Zn2+) 
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immobilized on the exterior surface of the nanoparticle to serve as binding sites for 
branched polypeptides with multiple pendant carboxylate side chains which act as the 
capping ligands. Luminescence resonance energy transfer (LRET) occurs between the 
loaded drugs DOX and CPT and the UCNPs, which results in a quenched UV-vis emission 
of the UCNPs. The LRET is eliminated upon drug release, which appears as an 
enhancement on the UV-vis emission of UCNP. The drug release was triggered by ATP, 
which caused a competitive displacement of the polypeptide from the MSN surface due to 
a mechanism of competitive binding and the stronger affinity between ATP and TDPA-Zn2+ 
immobilized on nanoparticle surface [141]. 
 
 
3.2. External stimuli-responsive MSNs 
The external stimuli employed to trigger the release from responsive nanoparticles include 
those that are remotely applied by the clinician, being under control at all times by the 
operator. Their main advantages include the possibility of being turned on and off as 
required and the ability of being applied locally into the site of the disease as desired. 
Many examples of MSNs externally triggered can be found in the literature (Figure 5), such 
as light, temperature, magnetic field or ultrasound (US). 
 
3.2.1. Light 
The use of different wavelengths light for triggering the cargo release from MSNs has 
become very popular in the last few years. The employed wavelengths include ultraviolet 
(UV), visible (vis) or near infrared (NIR), which makes this approach very versatile. In a 
similar way to the rest of external stimuli for triggering the release from nanoparticles, light 
present some benefits, such as its easy application by the operator from the outside of the 
body and the possibility of focusing to the targeted tissue, although the tissue penetrability 
is not as deep as other stimuli such as ultrasound. The most popular wavelengths 
employed in MSNs include UV-vis and NIR. Generally, UV-vis is normally employed for 
triggering the transformation of molecules or polymers because of the high energy of the 
photons. However, UV and visible light present low tissue penetration and potential 
damages to living systems. However, NIR operates in the biological transparency window, 
at which scatter and adsorption are minimalized leading to greater tissue penetration. 
 
3.2.1.1. UV-visible 
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Among all the possibilities, UV has been the most popular type of radiation to stimulate the 
cargo release from MSNs, because its high power is able to break bonds [142]. UV light 
can also provoke the isomerization of certain molecules that might trigger the release from 
MSNs in what are called nanovalves [143,144]. In this sense, azobenzene derivatives 
have been widely employed to block the pores since they can go through a trans to cis 
photoisomeriazation process that might trigger the drug release from MSNs [145]. 
Our research group developed a proof of concept using light as stimulus to trigger the 
release from MSNs [45]. In this work MSNs were covered with a shell made of proteins 
using a photosensitive linker that was cleaved under UV radiation at 366 nm. The protein 
shell was functionalized on the external face with transferrin, a well-known targeting ligand 
that would react with overexpress receptor on the surface of cancer cells. The idea was 
that once the tumor cells might have had internalized MSNs, the application of UV light 
would trigger the drug release. This approach might be suitable for treating tumors that are 
accessible for light irradiation, as it is the case of melanomas. 
However, UV light presents two main limitations: it might be toxic because of its high 
energy and it presents low penetration capability. As a possible alternative, we have 
developed a proof of concept using visible light to trigger the release from MSNs, because 
it is safer and presents higher tissue penetrability than UV light [146]. In this work we 
capped the pore entrances of MSNs with porphyrin-caps grafted through reactive oxygen 
species cleavable linkages. Although visible light has a more innocuous nature than UV 
light, its energy is high enough to activate some photosensitizers in the production of 
reactive oxygen species [147]. Our proof of concept benefits from the non-toxicity and 
great penetration capability of visible light and also presents a dual antitumor effect: the 
antitumor cargo released form the pores and the generation of reactive oxygen species. A 
similar dual approach on releasing cytotoxic drugs and generating singlet oxygen from 
MSNs was carried out using the photosensitizer chlorin e6 doped MSNs nanorods 
[148,149]. 
 
3.2.1.2. Near infrared 
Near Infrared possesses unique advantages such as deep tissue penetration together with 
minimum autofluorescence and tissue scattering. In fact, NIR offers the deepest 
penetration of light in living tissues, with a wavelength between 650 and 900 nm. The 
penetration depth of NIR ranges from 1 to 2 cm, which make this stimulus more 
appropriated for imaging applications than controlled drug delivery [150]. The high tissue 
penetration depth of NIR light together with unique drug delivery capabilities of MSNs can 
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be combined to design NIR triggered MSN based DDS [151]. The two most often 
approaches that have been developed include NIR-UV triggered drug release and NIR-
thermal triggered drug release. The former includes the lanthanide doped upconversion 
nanoparticles that can transfer NIR light into UV-vis light radiation [152]; and the later 
includes NIR-thermal converting nanoparticles, in which precious metal nanoparticles with 
NIR plasma resonance need to be used [153]. 
 
3.2.1.3. Upconversion 
Photosensitive nanocarriers able to act once localized in the tumor environment or the 
pathologically affected tissues must operate in the biological window. However, for most 
photosensitive nanocarriers, photoreactions are induced by UV or visible light. 
Conventional administration of UV light or visible light have limited biomedical applications 
since brings up severe concerns of uncontrolled damages to DNA and proteins of normal 
tissues and also suffers from very limited depth of tissue penetration. By contrast, NIR light 
is a better choice for clinical therapies since it induces minimal cell damage and also has 
very low light absorption by water and hemoglobin, leading to the maximum tissue 
penetration. Upconversion (UCN) provides an effective way to convert NIR light to UV-vis 
light for light-triggered release. UCN is a multiphoton process in which two or more low-
energy pump photons from the NIR are transferred to a higher-energy output photon with 
a shorter wavelength in the UV-vis region. Efficient transducer nanomaterials are based in 
lanthanide ions (such as Tm3+, Yb3+ an  Er3+) doped nanocrystals which lead to 
upconversion nanoparticles (UCNPs) with potential and significant biomedical applications 
[154]. UCNPs combined with a mesoporous silica shell lead to core@shell nanosystems 
UCNPs@MSNs for NIR light triggered drug release. 
For example, UCNPs@MSNs loaded with DOX and grafted with ruthenium complexes on 
the surface of the nanoparticles as photoactive molecular valves have demonstrated to be 
sensitive to ultralow-intensity NIR light. The ruthenium complexes are cleaved by 974 nm 
light with intensity as low as 0.35 W cm−2, which is lower than the maximum permissible 
exposure of skin (0.726 W cm−2), minimizing overheating problems and preventing 
photodamage to biological samples at such a low light intensity [155]. 
Recently, a polyelectrolyte bearing UV-labile pendant groups have been used as outer 
shell UCNPs@MSNs@polyelectrolyte, acting as gatekeeper since NIR light triggers the 
polymer layer disruption and drug release [156]. 
Multilayered conformation also makes possible the controlled release of nitric oxide when 
NO-releasing molecules are covalently linked to the silica as the outer shell. S-nitroso-N-
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acetyl-dl-penicillamine (SNAP) is a chemical progenitor of NO because it is sensitive to UV 
light for the release of NO. Therefore, continuous-wave NIR laser irradiation at 980 nm 
enables NO releasing from UCNPs@MSNs@SNAP in a light dosage-dependent manner 
and the effect has been investigated on platelet aggregation [157]. 
UCNPs@MSNs have been also reported for in vivo bioimaging in theranostics [158], Hg2+ 
sensing [159] due to the UCN luminescence or PDT, which uses UV-vis light to initiate a 
photochemical reaction between a photosensitizer and tissue oxygen to generate toxic 1O2 
that can damage cancer cells. Therefore, upon NIR irradiation, the emitted UV-vis light can 
excite photosensitizer molecules loaded in the UCNPs@MSNs nanocarriers to generate 
ROS for PDT. As an example, a photosensitizer for PDT treatment, zinc phthalocyanine, 
has been encapsulated in UCNPs@MSNs@lipid triple layer nanoparticles. With the help 
of the cross-linked lipid shell, the triple layer nanoparticle can prevent the photosensitizer 
leaking and particle aggregation and also be modified to target the lesions [160]. 
Other approaches achieve synergistic effects of chemotherapy and PDT. An 
UCNPs@MSNs that incorporates the photosensitizer chlorin e6 in the silica network and 
the anticancer drug DOX loaded into the mesopores was gated by grafting a thioketal 
linker onto the nanoparticles surface. Upon NIR irradiation, the upconverted luminescence 
derived from the core stimulates Ce6 to generate ROS for PDT. In addition, the thioketal 
“gate” also can be cleaved by these ROS to permit drug release [161]. In another work, the 
blue emission derived from the UCNPs upon NIR irradiation induces the break of the gate 
for DOX release and also excites the photosensitizer, which had been incorporated to the 
silica framework, to generate ROS for PDT [162]. 
 
3.2.2. Temperature 
Temperature can be employed as internal stimuli in certain pathologies, such as tumors, 
inflammation or infection processes, that can provoke moderate temperature increases of 
up to 4 or 5 oC [163]. On the other hand, temperature increases caused by other stimulus, 
such as the hyperthermia produced with magnetic fields, can also be employed to trigger 
the cargo release from MSNs. In general, water soluble polymers able to respond to 
temperature changes are the ideal candidates to cap the pores due to their reversible 
conformational changes in response to temperature and they can also contribute to 
improve the colloidal stability of the MSNs [164,165]. In this sense, the use of poly(N-
isopropylacrylamide) (pNIPAM) to cap the mesopores from MSNs is probably the most 
employed strategy. pNIPAM presents a lower critical solution temperature (LCST) at 32 
oC, which means that the polymer changes from hydrophilic to hydrophobic state when the 
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temperature might be above the LCST [163]. There are also different approaches with 
several analogs to pNIPAM that have been employed to tune the responsive temperature 
as desired [166]. 
In the last few years, PEG acrylates have been evaluated as substitutes of pNIPAM 
analogs because of the better biocompatibility of PEG and the corresponding monomers. 
In this sense, it is possible to adjust the monomer ratio to tune the LCST temperature, 
offering the possibility of changing the responsive temperature as desired [167]. 
In a different approach, a coiled coil motif was employed to block the pores preserving the 
release of their cargo. The coiled coil motif consisted on two alpha-helices coiled around 
each other in a rope-like fashion, and when heated over physiological temperature the 
coiled coil structure was disassembled, triggering the release of the cargo molecules [168]. 
3.2.3. Magnetic fields 
Magnetic fields have been widely employed in nanomedicine because they can 
magnetically guide the nanoparticles when using a permanent magnetic field or increase 
the internal temperature when employing an alternating magnetic field. The classical 
approaches of magnetic responsive MSNs are based on superparamagnetic microspheres 
with a Fe3O4@SiO2 core and a mesoporous silica shell [169]. In a similar approach, 
spheres with a core of magnetic Fe3O4/Fe and a mesoporous silica shell able to 
encapsulate ibuprofen have been explored as drug nanocarriers [170]. 
Our research group has developed magnetically responsive MSNs incorporating 
superparamagnetic iron oxide nanoparticles of ca. 5–10 nm into the silica network during 
the synthesis of MSNs and capping the pore entrances with the thermosensitive pNIPAM 
to close the pore entrances to retain the cargo inside avoiding premature release 
[171,172]. Then, the application of an alternating magnetic field to the responsive 
nanocarriers led to an increase into the local temperature, which promoted a change on 
the conformation of a temperature responsive polymer and leaded to the release of the 
cargo. In a similar approach, we added a polyamine to the thermoresponsive capping 
polymer so different proteins could be retained within the polymeric shell. The idea was to 
deliver two types of cargoes: therapeutic agents inside the mesopores and biomolecules 
such as certain proteins on the shell of the nanocarriers [173]. Then, the application of an 
alternating magnetic field provoked that the iron oxide nanoparticles increased the local 
temperature so the conformation of the thermoresponsive polymer changed, opening the 
pore entrances and triggering both cargoes, therapeutic molecules and biomolecules. 
In a different approach we developed magnetically responsive MSNs grafting a single DNA 
strand to their surface and then loading the cargo inside the pores [174]. Separately, the 
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complementary DNA sequence was attached to magnetic iron oxide nanoparticles of ca. 5 
nm. Then, both DNA-MSNs and DNA-iron oxide nanoparticles were mixed so DNA 
hybridized with the subsequent capping of the pores. The employed DNA sequence 
presented a melting temperature of 47 oC, so the alternating magnetic field increased the 
temperature of the iron oxide nanoparticles encapsulated into the MSNs network and their 
environment. This led to the double-stranded DNA melting, which promoted the aperture of 
the pores capping and the subsequent and cargo release. One of the interesting aspects 
of this proof of concept was that the DNA coupling was reversible, so when the magnetic 
field might be switched off, the system might reach physiological temperature and the DNA 
strands would hybridize again capping the pores. Then, they could be opened and closed 
again, leading to a pulsatile or on-off release mechanism. 
3.2.4. Ultrasound 
Ultrasound is considered as one of the most promising triggers for drug delivery 
nanosystems, although it has already been extensively employed in the clinic. The reason 
for such interest relays on its capacity to non-invasively penetrate deep into the living 
tissues without damaging them, among others. The thermal, mechanical and chemical 
effects from US have been employed for developing different US responsive nanocarriers, 
such as liposomes, micelles and polymeric nanoparticles. This sudden interest of the drug 
release scientific community is due to the characteristics that ultrasound can offer to the 
field, besides the high tissue penetration capacity: non-invasiveness, portability, economy 
and spatiotemporal controllability. As a consequence, US has become one of the most 
promising options for controlling the drug delivery within the biomedicine field [175]. 
The first combination of US with mesoporous silica was carried out using bulk mesoporous 
materials, such as MCM-41, and capping the pores with poly(dimethylsiloxane). The 
application of US triggered the release of the previous loaded ibuprofen, which was 
employed as a model drug [176]. Afterwards, ultrasound was applied to MSNs motivated 
by the fast development of MSNs with nanomedicine applications in the last few years 
[177–179]. However, if we compare US with other external stimuli such as light or 
magnetic field applied to MSNs, a delay in terms of research and publications on US-
responsive MSNs can be observed. 
Vallet-Regí group recently started to work with this stimulus developing US-
sensitive MSNs in which the pore entrances were capped with a specially designed 
co-polymer [180]. 
The designed co-polymer presented a labile acetal group that can be cleaved upon 
US application leading to a different molecule with changed hydrophobicity. This 
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phase transformation from hydrophobic to hydrophilic changed the polymer 
conformation and, consequently, opened the pore entrances and triggered the 
cargo release. These designed US-responsive MSNs were not toxic in vitro. 
Additionally, none of the by-products from the nanocarriers before and after 
ultrasound irradiation affected the cell viability. Moreover, the US exposure at 1 
MHz and 15 W did not damage relevant biological molecules. The US 
responsiveness was retained after cellular internalisation, as observed loaded with 
doxorubicin (anticancer drug) and evaluated with prostate cancer cells (LNCaP). 
Before US irradiation no cellular toxicity was observed, which meant that the pores 
were appropriately capped, and no premature release took place. However, when 
the MSNs were exposed to US, cancer cells were killed, showing the capacity of the 
proposed system to be used in a potential cancer therapy. 
As it has been mentioned throughout this manuscript, nanocarriers can be targeted 
and accumulated into tumours through either passive and/or active targeting. Both 
approaches are based on developing nanocarriers able to circulate within the blood 
stream for a long time. In this sense, nanoparticles should be stable in physiological 
media and our previously developed US-sensitive MSNs lacked this property. The 
reason for that was the presence of the co-polymer on their surface that made them 
highly hydrophobic at physiological media which leaded to nanoparticle 
aggregation. Therefore, Paris et al. covered those US-sensitive MSNs with a layer 
of PEG to prevent aggregation and we grafted active targeting moieties to develop 
a PEGylated and modularly targeted US-responsive nanocarrier [181]. 
Although MSNs can accumulate into tumour tissue through the EPR effect or the 
active targeting moiety, the treatment might not be completed until the cargo could 
be released into the cancer cells. Therefore, it is necessary for the nanoparticles to 
be up taken by the cancer cells, and this might be enhanced by the presence of 
internalisation ligands (such as certain targeting agents) or positively charged 
moieties on the surface of the nanoparticles. Paris and co-workers developed a 
novel strategy using MSNs positively charged, as the mechanism of internalisation, 
which was hidden by grafting PEG chains on the nanoparticle through a 
thermosensitive linker. Then, the application of US produced a local increase of 
temperature which leaded to the cleavage of the PEG chains from the nanoparticles 
exposing the positive charges of the nanoparticles and, therefore, favouring the 
cellular uptake [182]. 
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3.3. Multi-stimuli responsive MSNs 
The precise control of the specific delivery of therapeutics at the target tissue or cells can 
be ensured by designing controlled drug release triggered responsive to two different 
stimuli that potentially could work synergistically to ensure drug release only at the target 
site. The MSNs versatility and functionalization capabilities makes them very attractive to 
incorporate at least two responsive functional moieties in the same nanosystem (multi-
stimuli responsive delivery). Hence, the pore blockers may be opened either by one or 
another stimulus or simultaneously by both. In other situations, it is proposed to use a 
stimuli cascade in which one stimulus triggers the performance of the event that uncap the 
MSNs or leads to a sequential release of different cargos. Different combinations of 
endogenous, exogenous or both kind of stimuli are described in this section. 
Multidrug resistance (MDR) is a great problem in successful chemotherapy. In this sense, 
a study by Han et al. focused on hybrid lipid-capped MSNs (LTMSNs) as redox and pH 
stimuli-responsive drug release to circumvent MDR [183]. Lipid molecules composing 
polymer D-α-tocopherol-PEG-succinate were subsequently added to self-assemble into a 
surrounded lipid layer via hydrophobic interaction acting as smart valves to block the pore 
channels of carrier. This system loaded with DOX induced higher uptake efficiency, 
cytotoxicity, and increased intracellular accumulation in tumor MCF-7/Adr cells. 
MSN-AuNPs through ion-ligand interactions have demonstrated to release the drug 
molecules under both pH and ATP concentration stimuli. The MSNs externally modified 
with -NH2 groups were capped with L-cysteine functionalized gold nanoparticles through 
Cu2+ ions. A rapid release of the guest molecule from the mesoporous silica host at pH 
below 5 was found because the ζ-potential of the cysteine-coated AuNPs switches from 
negative to positive. At the same time, the disruption of the capping by formation of ion-
ligand bond between Cu2+ and ATP through a competitive binding mechanism is 
responsible for the AuNPs removal. Therefore, under both stimuli, the AuNPs leave the 
MSN surface remaining associated with Cu2+, then allowing the release of the entrapped 
drugs and minimal release of Cu2+ [184]. 
pH- and glucose-stimuli responsive MSNs for the controlled release of insulin were 
prepared by tethering insulin molecules onto the exterior surfaces of boronic acid-
functionalized MSNs via gluconic acid linker groups. The surfaces of the resulting MSNs 
were coated with the adhesive and pH-sensitive polymer polyacrylic acid, which was used 
to protect the entrapped insulin from undergoing possible enzymatic degradations in 
locations such as the gastrointestinal tract. Besides, the polyacrylic acid, which has 
excellent dispersibility and adherence to the mucosa, might also allow the permeation of 
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such nanoparticles through the colon, and thereby improves their potential application for 
insulin delivery. Because of their shrinkage at low pH and swelling at high pH, the 
polyacrylic acid-coated MSNs exhibited pH dependent insulin release properties. In 
addition to pH, glucose was shown to trigger the release of insulin from the nanoparticles, 
which demonstrates the nanosystem dual stimuli-responsive properties for the controlled 
release of insulin [185]. 
In the same line, polyacrylic acid has been obtained through the surface-initiated atom 
transfer radical polymerization at the mesopore openings and after glycosylation the 
chains were cross-linked through the formation of boronate esters to block the pores of 
MSNs. The boronate esters disassociated in the presence of glucose or in acidic 
conditions, which lead to opening of the mesoporous channels and therefore, combination 
of both pH and glucose stimuli exhibited an obvious enhanced release capacity in mild 
acidic conditions [186]. 
The fact that the presence of both a low pH and sugar molecules provides cooperative 
effects which together control the rate of release in boronic acid-based MSNs platforms 
has also been demonstrated by the group of Sttodart and Zink [187]. 
A multi stimuli responsive DDS based on dual enzyme and GDH sensitive was studied by 
Wang et al. Sulfhydryl and amino-functionalized MSNs (SH/NH2-MSNs) were grafted with 
multifunctional HA derivatives to control drug release and reverse MDR [188]. The DOX 
loaded multifunctional HA derivatives modified MSNs were enzyme and redox sensitive, in 
respond to the intracellular stimuli of hyaluronidase and GSH successively. In tumor MCF-
7/ADR cells, this DDS was efficiently internalized and endocytosed, inducing a strongest 
cytotoxicity. In vivo, MCF-7/ADR tumor-bearing xenograft mouse models indicated that 
nanosystem enhanced tumor-targeting capacity reversing cancer MDR. 
For multidrug delivery, different drugs can be released either simultaneously or in 
sequential method. A dual-stimuli DDS which is capable of releasing two different sized 
drugs step by step was prepared by capping the mesopores with β-cyclodextrin (β-CD) 
through photocleavable bonds to control its detachment. The cavity of β-CD was blocked 
by ferrocene through the host-guest interaction between ferrocene and β-CD. The small 
cargo can be released by the escape of ferrocenium under +1.5 V electro-stimuli. 
However, the bigger sized cargo was released from the MSN only after the detachment of 
the β-CD cap from the MSN surface upon UV irradiation. Therefore, the different sized 
cargoes were released successfully step by step under external electro stimuli and UV-
light, respectively [189]. 
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The drug loading and transportation of drugs with no premature release to specific 
locations can be also controlled with dual-responsive polymers grafted on the MSNs 
surface that act as gatekeepers of the mesopores. For example, a temperature and 
ultrasound responsive copolymer allows the cargo loading at low temperature (4 °C), 
taking advantage of the coil-like or open conformation that the polymer presents under 
these conditions. When the temperature is increased to 37 °C, the copolymer changes to 
an insoluble collapsed state and the nanogates are closed retaining the cargo into the 
pores at physiological temperature. Upon ultrasound irradiation, the hydrophobic moieties 
of the copolymer are cleaved, leading to an increase of the hydrophilicity of the polymer 
and, therefore, its conformation changes toward coil-like opening the gates and releasing 
the entrapped cargo [180]. 
In a similar fashion, a temperature and ROS-responsive copolymer tethered to the outer 
surface of MSNs allows cargo loading in cold water, and subsequent closing of the 
mesopores by raising temperature at physiological conditions. Then, upon the stimulus of 
H2O2, the hydrophobic phenylboronic acid groups in the copolymer backbone are promptly 
oxidized to hydrophilic acrylate, which increases the solubility and open the nanogates at 
physiological temperature, inducing the release of the cargos from the pores [190]. 
The combination of therapeutic strategies has been proven to be a complementary 
strategy for traditional chemotherapy [1], among which the combination of chemotherapy 
and hyperthermia therapy is widely applied. Shu et al. developed a thermo/pH-dual-
stimulus controlled drug release system by anchoring a thermo/pH-responsive polymer 
poly((N-isopropylacrylamide)-co-methacrylic acid) onto MSNs, functionalized as the 
gatekeeper [191]. The pNIPAM moiety facilitates the pores of MSN opens by a thermo 
induced collapse of the polymeric chain. The moiety of MA is pH sensitive, inducing the 
opening of gatekeeper followed by the release of loaded drugs, DOX and near infrared 
absorbing phototherapeutic agent (indocyanine green, ICG). DOX-ICG-MSN@pNIPAM 
nanocarriers enhanced the HeLa tumor cytotoxicity with a synergistic chemo-photothermal 
effect, with a favorable photothermal conversion capability under NIR irradiation for 
controlled drug release. In the context of combination therapy, Wang et al. fabricated a 
novel visible light and pH responsive polymer-coated MSN hybrid system by electrostatic 
interaction between MSNs and the perylene-functionalized polymer [192]. Loaded DOX 
into the MSN was efficient released at acid pH and induced a significant decreased of 
MFC-7 cancer cells, and these results were synergistic enhanced when combined with 
visible light irradiation. These nanohybrids could be a great potential for cancer therapy, 
counteracting the hard conditions of UV light or extreme pH stimulation. 
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The combination of chemotherapy and PTD has been also described in a multifunctional 
nanoplatform with pH-responsive drug release and NIR light-triggered PDT in a multilayer 
core@shell@shell structure. The UCNP core was coated with a dense silica shell 
embedded with the photosensitizer, methylene blue trapped in the silica matrix. After that, 
an outer most mesoporous silica shell was the nanoreservoir to load DOX and 
polyethyleneimine acts as a gatekeeper to block the pore channels preventing the loaded 
DOX from leaking. Distortion of the polyethyleneimine layer under acidic conditions will 
release the loaded DOX. Besides, 1O2 species were generated with 980 nm light 
irradiation because the embedded photosensitizer in the sandwich shell are activated by 
the upconverted 660 nm red light from the UCNP core [193]. 
In a recent example, the trigger to open the pores is self-generated upon the application of 
an external stimulus. DOX loaded MSNs are capped with a Gd-DOTA complex through a 
1O2 sensitive aminoacrylate linker and a (PEG)-conjugated chlorin e6 is also attached to 
the MSNs surface as the ROS generator. The nanosystem is effectively accumulated in 
tumor tissue through passive targeting and, since the Gd-DOTA complex is a T1-contrast 
agent, the tumor site can be readily detected using MR imaging, allowing for site-specific 
laser irradiation to generate 1O2. Upon 660 nm laser irradiation, the gatekeeper was 
cleaved by the generated 1O2 and the DOX exhibited a rapid release. The in vivo assays 
showed that tumor growth was significantly suppressed with this multifunctional 
nanosystem [194]. 
González-Alvarez et al. reported a three gated MSNs able to deliver their cargo triggered 
by different stimuli: redox environment by a disulfide bond (S1), enzymatic hydrolysis (S2), 
and a surfactant or being in contact with cell membrane (S3) [195]. The nanocarrier was 
able to deliver cargo (safranin O) only in the presence of the corresponding stimuli: a 
reducing agent (GSH) for S1, pancreatin for S2, and a surfactant for S3. In Caco-2 
monolayers, a model for drug transport in the intestinal mucosa, cell up take results 
indicated that S2-MSNs were successfully internalized by these cells via endocytosis. S2-
MSNs with safranin O were included in an enteric coated capsule with Eudragit FS 30 D to 
target colon. In rats, the coated capsule containing the MSNs delivered S2 nanoparticles 
in colon tissue, releasing safranin O inside the colonic cells after the enzymatic stimuli and 
increasing the safranin O levels as well in colonic tissue. 
 
4. Conclusion 
The unique and groundbreaking features of MSNs as drug delivery nanocarriers have 
attracted the attention of the nanomedicine research community. A huge amount of work 
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has opened up with outstanding potential applications for these advanced controlled drug 
release systems. However, their translation to the clinic remains a challenge because 
there are two major issues that should be solved: the standardization of materials by 
appropriate synthesis and physico-chemical characterization, and the homogenization of 
the biological evaluation. The first premise is feasible, and it has been already properly 
addressed by some authors, avoiding variability and lack of reproducibility. Furthermore, 
the standardization of the biological evaluation, although complex, is mandatory since the 
variation of the experimental designs for the in vivo studies is too broad to obtain valid 
conclusions. 
 
5. Expert opinion 
As it has been demonstrated both in this review and the previous one from 2015, the use 
of MSNs is a very prolific and competitive field of research. In fact, these types of particles 
have proved to be outstanding platforms for the development of nanosystems capable of 
fighting numerous types of cancer and bacterial infections at least at the basic research 
level. This is possible thanks to the particular structure presented by the MSNs, which is 
capable of loading and retaining drugs within its porous matrix. However, the advance of 
knowledge and the need to transfer these materials towards advanced preclinical models 
have revealed new aspects and effects that must be considered for the design of medical 
nanosystems. In a general way, these aspects range from classical physicochemical 
parameters to the presence of elements of cellular/bacterial recognition, passing through 
the highly convenient payload retention or the in vivo determination of particle trafficking.  
 
Currently, nanomedicine-based treatment of cancer relies on the EPR effect, a 
phenomenon that accumulates nanoparticles and macromolecules into most of tumor 
masses. However, those nanotech-drugs have a long journey before they can reach this 
final destination. Indeed, in this way the particles must skip the constant vigilance of the 
immune system and avoid self-aggregation to remain in the bloodstream long enough to 
reach the tumors. To do so, the particles must be able to repel the numerous adherent 
opsonins present in the blood serum whose purpose is to trigger the excretion of 
xenobiotics. The most common resource for those purposes is the use of hydrophilic 
polymers such as PEG that effectively protect against the deposition of proteins and 
prevent interaction between particles. However, the indiscriminate use of PEG in the 
pharmaceutical industry has begun to generate sensitivity [196], which is a great 
disadvantage for the development and commercialization of nanotech-drugs. To avoid this 
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dramatic effect, the scientific community has begun to develop alternative strategies. On 
the one hand the use of zwitterion components permits to create low-immunogenic 
hydrophilic coatings suitable for achieving high blood circulation times and low hemolytic 
materials. Whilst on the other hand, the development of bioinspired coatings by the 
selection of proteins of interest could be employed for creating artificial protein-corona 
coatings able to avoid the action of immune system. 
 
Apart from an adequate shape and size and the ability to overcome the action of the 
immune system, the lone EPR effect may not be enough to efficiently attack tumors. This 
is partially because a tumor is formed by a large number of cells that coexist in different 
states (necrosis, apoptosis, cell constrainment, etc.) and together with support cells 
sequestered by the tumor (macrophages or vasculature epithelial cells among others). So 
it is imperative that particles are able to efficiently discriminate between such cell 
populations. That has been accomplished by the use of active targeting modification, in 
order to turn particles from passively accumulated carriers into cell-homing systems. 
Beyond classical recognition by affinity (aptamers, proteins and ABs), the current 
development of targeting tags seems to be shifted to less specific but more versatile 
interaction. For example, short peptides and small molecules seem to be the new standard 
as they could be easily prepared and modified and coupled. Moreover, the recent 
advances on multi-targeting also offer interesting approaches like tissue-to-cell or cell-to 
organelle targeting, which could be convenient for more precise guidance or more efficient 
killing abilities. Apart from this strategy, the preference for natural or biogenic components 
seem to be a common denominator as their utilization has grown with the promise of 
obtaining an easier transfer to preclinical testing. 
 
Besides from the improvement in the recognition of cell and bacteria populations by 
nanoparticles, other relevant growing field of nanomedicine is enhancing the killing 
capacity of the systems. To this end, two differentiated strategies have been followed, 
either the simultaneous co-administration of drugs or the combination of physicochemical 
effects together with traditional drugs. Within the first approach, the use of siRNAs for the 
treatment of cancer and of specific antimicrobial peptides for the treatment of infection 
stand out, while within the second approach the examples with silica-containing 
nanocomposites able to generate thermal stress (hyperthermia and photothermal effects) 
or oxidative (PDT) are the most representative. The use of combination therapy of drugs 
using either siRNAs or antimicrobial peptides has the advantage of using compounds with 
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very little toxicity able to induce great effects; although their long-term stability is often 
comprised due to their fast degradability in living systems. On the other hand, the use of 
thermal or oxidative stress show the enormous advantage of being able to be controlled at 
will by the clinician, even at the cost of presenting a possible chronic toxicity if the 
sensitizers are not quickly cleared or excreted. 
 
In addition to all topics aimed at improving biosafety of MSNs in living systems, there must 
be also considered the porosity, which is exclusive to MSNs. As already indicated, the 
presence of those pores in the MSNs makes them exceptional materials for the loading of 
chemotherapeutic drugs and antibiotics. However, in the absence of control elements, 
such drugs will leak from the porous matrix following concentration gradients. This results 
in substantial drug losses and off-target delivery that must be minimized. Fortunately, 
nowadays there are many systems able to regulate the permanence of drugs within the 
porous matrix. However, the trend observed from latest publications seems to indicate that 
these systems are developed under three common guidelines: a preference for 
biodegradable and easily-clearable materials, the ability to respond to multiple stimuli with 
the idea of increasing their potential applicability and finally, the possibility for further 
functionalization with either active targeting moieties or immune-stealth modifications.  
 
Besides the modifications needed to turn bare MSNs into high-performing drug 
nanocarriers, there are also several issues to be addressed regarding the nanosystems 
themselves. The following are worth to be mentioned: (1) there is no homogeneity nor 
common criteria about the nature and size of connecting fragments; (2) there is a lack of 
knowledge about the possible toxic behavior of composite species like UCNs, which use 
fluorides and rare-earth ions, or AuNPs that do not biodegrade and finally, (3) the way a 
set of given materials are structured may lead to different bioavailabilities / compatibilities 
depending on their disposition. The design of multi-stimuli responsive MSNs should not be 
too complex to facilitate the translation into the in vivo study and the use of the stimulus-
response nanosystem should demonstrate clear advantage in clinical settings. In any 
case, the following aspects must be taken into account. First, that the biosuitability of the 
whole will be determined by the least biocompatible component; and second, that 
mesoporous silica has become a connective element in many hybrid nanocomposites. 
This apart from auguring a new era in the development of multi-therapeutic nanoplatforms 
also demands from extensive knowledge of silicon metabolism and possible long-term side 
effects.  
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Moreover, there is also a big gap regarding the available in vivo experiments, as most 
examples are based on human cell xenografts implanted in immunosuppressed murine 
models; which have demonstrated to be highly limited to obtain reliable conclusions. For 
example, murine xenografts differ from actual diseases in both the cells populations that 
form the tumor and in the degree of development reached before being treated. But in 
addition, very few articles deal with the fate and ways of clearance of nanomaterials, which 
probably would be dangerously accumulated. Therefore, it would also be convenient to 
undertake a systematic study on how different particles (size, shape, pore symmetry and 
connectivity and chemical composition) are more suitable to be used as nanotech drugs. 
And hence, within these parameters, to know their fate in living systems (processing, 
accumulation and elimination in living organisms) prior to develop novel strategies and 
composites would be also appropriate. Accurate pre-clinical animal studies using MSNs 
are needed to demonstrate its worth in the field of Nanomedicine aimed at the MSNs 
clinical breakthrough in the next future. 
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Figure legends 
 
Figure 1: Transmission electron microscopy of several kinds of MSNs for different 
biomedical applications, showing (1st row) center-radial porosity (MSNR) with different 
particle and pore size (2-12 nm); (2nd row) longitudinal or 2D-hexagonal structure (MSNL) 
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with different particle size (150-50 nm); (3rd row) MSNs coated with different inorganic 
nanoparticles such as gold nanorods (MSN-AuNR); gold nanoparticles (MSN-AuNPs), 
silver nanoparticles (MSN-AgNPs) and magnetite nanoparticles (MSN-Fe3O4); (4th row) 
core@shell structure with hydroxyapatite nanorods (HANR), gold nanorods (AuNR) and 
magnetite nanoparticles (Fe3O4) as core. 
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Figure 2: Main factors influencing MSNs biodistribution and its accumulation in defense 
organs. 
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Figure 3: (Top) Schematic representation showing the more representative approaches 
described up to date, PEGylation and zwitterionization, to increase the resistance of non-
specific protein adsorption and the stealthy to the macrophages. (Bottom) Confocal 
microscopy studies showing the macrophage-uptake of different MSN-type systems (bare 
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MSNs, MSN-Zwitter and PEGylated MSN). The staining corresponds to cell-nuclei (DAPI, 
blue), cell membrane and cytoskeleton (phalloidin, red) and nanoparticles (fluorescein, 
green). Internalized nanoparticles are highlighted with yellow arrows, while those located 
in the outer area are marked with white arrows. Scale bar: 5 µm. 
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Figure 4: Different strategies to provide active targeting to MSNs. 
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Figure 5: Schematic representation of internal or endogenous stimuli to the pathological 
microenvironments (pH, redox, enzymes and small molecules) and external or exogenous 
(magnetic field, light, temperature and ultrasounds) stimuli that can be used to trigger on 
demand drug release from MSNs. 
 
 
Table 1. Comprehensive list of active targeting ligands employed for favoring 
uptake of MSNs onto different cell lines. 
Substrate Receptor Target cell line(s)  Ref. 
    
Antibodies    
Anti-Mucin 1, TAB-004 Mucin 1 glycoprotein 4T1, MMT [37] 
Anti-TRC105  CD105 HUVEC, 4T1 [38] 
Ri7  Transferrin (Mouse) bEnd5, Neuro-2a [39] 
B220  CD45R CALM-AF10 [40] 
Anti-EGFR  HER1 A549 [41] 
Trastuzumab  HER2 SK-BR3, BT474 [42-44] 
    
Proteins    
Transferrin  Transferrin receptor 
BT-549, HeLa, PANC-1,  
HuH-7, HT1080 
[45-47] 
ConA  Sialic acid receptor HOS [48] 
Aleuria aurantia lectin  Sialyl-Lewis X antigen DLD-1 [50] 
TEM1-scFv  TEM1 Ovcar5  [51] 
Rec. GST-HER2-Afb  HER2 SK-BR3 [52] 
    
Peptides    
RGD family 
GFLGR7RGDS  
αvβ3 integrins 
U87-MG, MDA-MB-435, 
MDA-MB-231, HepG2, 
Neuro-2a, HeLa, SCC-7, 
HT-29, A375, MCF-7. 
[54] 
NGR family  CD13 BCEC, C6  [55,56] 
IL-13 IL-13R-α2 U251 [57] 
CDX  nAChR BCEC [58] 
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NAPamide  Melanocortin Melanoma cell lines [59] 
Bld-1  
Formyl peptide 
receptor 1 
HT-1376, T-24 [60] 
cA6  CD44 MDA-MB-231, SK-BR3  [61] 
t-Lyp-1  NRP1, NRP2 MDA-MB 231, HUVEC [62] 
TAT peptides  Iα/β HeLa; MCF-7/ADR [63] 
Polylysine  
Unknown 
(electrostatic) 
HeLa [66] 
BMP-2 derived  BMP-2 BMSC [68] 
    
Aptamers    
NCL/AS1411  Nucleolin 
MCF-7, SW480, PANC-1, 
PC3, MDA MB-231 
[71,72,7
5] 
HB5  HER2 
SK-BR3, MCF-7, MDA-
MB-231,  
[73] 
EpCAM  EpCAM 
HepG2, SW480, SW620, 
HT-29, HEK-293T, Y79, 
WERI-Rb1, Ramos B 
[74-76] 
MUC-1  Mucin 1 glycoprotein 
MDA-MB-231, C26, 
A549, MCF-7, CHO-K1, 
A2780 
[77] 
YQ26 CD105 HEK-293, HUVEC, 4T1 [78] 
    
Saccharides    
Hyaluronic acid CD44, CD168, HARE 
HepG2, MDA-MB-231 
HEK-293, HTC-116, 
Ovcar8  
[80-83] 
    
Small molecules    
Folic Acid FR-α 
HepG2, PANC-1, U2Os, 
MDA-MB-231, SK-BR3, 
HeLa, MCF-7, MiaPaCa-
2 
[84–87] 
Biotin BR HOS, HeLa, MDA-MB- [88–91] 
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231,  
Vitamin B12 TCII-R Not tested [92] 
Phenylboronic acid Sialic acid receptor HepG2 [93] 
TPP cations 
Unknown 
(electrostatic) 
Mitochondrion [94,95] 
Guanidinium cations 
Unknown 
(electrostatic) 
Mitochondrion [96] 
3-ABG NET NB-1691 [97,98] 
    
Double targeting    
RGD / TAT  αvβ3 integrins / Iα/β HeLa [100] 
RGD / IL-13 
αvβ3 integrins/ IL-13R-
α2 C6, HUVEC [101] 
FA / Dex FR-α / GCR HeLa, HEK-293 [102] 
FA / TPP FR-α / Mitochondrion LNCaP [104] 
Biotin / TPP BR / Mitochondrion HOS [105] 
    
 
Receptors: BR: biotin receptor; CD13 (aminopeptidase N, APN): cell membrane alanyl 
aminopeptidase; CD44 (P-glycoprotein 1, Pgp-1): Multifunctional Cell Surface Adhesion 
Receptor; CD45R (PTP): Protein tyrosine phosphatase; CD105 (Endoglin): type I 
membrane glycoprotein; CD168 (RHAMM, HMMR): Hyaluronan-mediated motility 
receptor; FR-α: Folic acid receptor; GCR: Glucocorticoid receptor; HARE (Stabilin-2): 
Human Hyaluronan Receptor for Endocytosis; HER1 (EGFR, ErbB1): human epidermal 
growth factor receptor 1; HER2: human epidermal growth factor receptor 2; HER2/neu 
(ErbB2, CD340): Tyrosine-protein kinase receptor; Iα/β: Importins α and β; IL-13R-α2: 
Interleukin-13 receptor α2; nAChR: Nicotine-Acetylcholine Receptor; NET: Norepinephrine 
transporter; NRP1 and NRP2: Neurophilins 1 and 2, coreceptors for vascular endothelial 
growth factor (VEGF); TEM1: antitumor endothelial marker 1; TCII-R: Transcobalamin 2 
receptor. Cell Lines: Blood: Ramos: Burkitt lymphoma; Bone: BMSC: Bone 
Mesenchymal Stem Cells; HOS: Human osteosarcoma; Bladder: HT-1376: Bladder 
carcinoma; T-24: Bladder carcinoma; Brain: BCEC: brain capillary endothelial cells; NB-
1691: Neuroblastoma; U87-MG: Human primary glioblastoma; U251: Human Astrocytoma; 
Breast: BT474: Human breast cancer cell line; BT-549: Human breast carcinoma cell line; 
MCF-7: Human breast cancer cell line; MCF-7/ADR: human breast cancer (doxorubicin 
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resistant); MDA-MB-231: Human breast adenocarcinoma; SK-BR3: Human breast 
adenocarcinoma cell line; Cervix: HeLa: Human cervix epithelioid carcinoma; Intestine 
and Colon: C26: Human colorectal cancer cells; DLD-1: Colon adenocarcinoma; HT-29: 
Human colorectal adenocarcinoma; HCT-116: Human colon carcinoma; SW480: Colon 
adenocarcinoma; SW620: Colon adenocarcinoma; Epithelia: HT1080: Human 
fibrosarcoma; HUVEC: Human umbilical vein endothelial cell line; Eye: WERI-Rb1: Human 
Retinoblastoma; Kidney: HEK-293: Human embryonic kidney 293 cells; Liver: HepG2: 
Human hepatoblastoma-derived; HuH-7: Human hepatoma; Lung: A549: Human Lung 
carcinoma; Pancreas: MiaPaCa-2: Human pancreatic carcinoma; PANC-1: Human 
pancreatic carcinoma, epithelial-like cell line; Ovarian: A2780: human ovarian cancer cells 
(paclitaxel resistant); Ovcar: Human ovarian serous adenocarcinoma; Prostate: LNCap: 
androgen-sensitive human prostate adenocarcinoma; PC3: human prostate cancer; Skin: 
A375: Human amelanotic melanoma; MDA-MB-435: Amelanotic melanoma; SCC-7: 
Squamous cell carcinoma; Murine Lines: bEnd5: mouse brain endothelioma; C6: Rattus 
norvegicus brain glioma; CALM-AF10: Murine acute myeloid leukemia ; CHO-K1: Chinese 
hamster ovary; 4T1: Mus musculus mammary gland tumor; MMT: Murine mammary 
epithelial cancer cells; Neuro-2a: Mouse neuroblastoma. Abbreviations: Rec. GST-
HER2-Afb: Recombinant glutathione-S-transferase-HER2-Affibody protein. Adapted and 
updated for the present work from reference [1]. 
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Table 2. Reviewed stimuli employed for drug delivery using MSNs. 
Stimuli Mechanims Ref. 
   
Internal stimuli 
pH 
Acidic cleavage (chemical) [48, 112, 113] 
Host-guest interaction [114, 115] 
Endosomal and lysosomal acidic pH [116, 118] 
Self immolative polymers [117] 
   
Redox 
S-S cleavage disassembly [119, 121] 
S-S cleavage unfolding [122] 
Redox induced solubility shift [123] 
   
Enzymes 
Peptide sequence cleavage [54, 124] 
Prodrug conversion [125] 
   
Small molecules 
Glucose concentration [126, 127] 
Glucose-mediated response to H2O2 [128] 
Generation of additional ROS species via 
Fenton reaction or α-tocopheryl 
[132, 133] 
H2O2 rich microenvironment [134] 
H2O2 or NO concentration [135] 
Competitive binding or displacement 
reactions in the presence of ATP 
[140, 141] 
   
External stimuli 
Light 
UV-vis [45, 146, 147, 
148, 149] 
NIR [151] 
NIR to thermal conversion: photothermia [153] 
conversion of NIR light to UV-vis light: 
upconversion 
[152, 154, 155, 
156, 157, 158, 
159, 160, 161, 
162] 
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Temperature 
Conformational changes in polymers:  
pNIPAM and analogs [163, 164, 165, 
166] 
PEG acrylates [167] 
Disassembly of coiled coil motifs [168] 
   
Magnetic fields 
Increase of temperature under the action of 
an alternating magnetic field 
 
Superparamagnetic cores in core@MSNs: 
Fe3O4 and Fe3O4/Fe cores 
[169, 170] 
IONPs in the silica network [171, 172, 173] 
IONPs as mesopore caps [174] 
   
Ultrasounds MSNs capping with a copolymer containing 
a labile acetal group which is cleaved upon 
US application. Change of polymer 
conformation due to hydrophobic to 
hydrophilic transformation. 
[180, 181, 182] 
   
Multi-stimuli responsive MSNs 
Dual responsive 
MSNs 
pH or ATP concentration [184] 
pH or glucose concentration [185, 186, 187] 
Enzyme (hyaluronidase) and redox (GSH) [188] 
Sequential release of 
different sized cargos 
Electro-stimuli and UV irradiation [189] 
Use of dual 
responsive polymers 
cargo loading at 4 °C and conformation 
change at 37 °C: 
 
upon US irradiation [180] 
upon H2O2 stimulus [190] 
dual-responsive polymers as gatekeepers:  
pH and thermoresponsive [191] 
pH and visible light responsive [192] 
Combination of Drug release under acidic pH and 1O2 [193] 
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chemotherapy and 
PTD 
generation with NIR irradiation 
1O2 generation upon 660 nm irradiation and 
gatekeeper cleaving by the generated 1O2 
[194] 
Three gated MSNs Redox, enzymatic hydrolysis and contact 
with cell membrane 
[195] 
   
 
Abbreviations: ATP: Adenosine triphosphate; GSH: Glutathione; IONPs: Iron oxide 
nanoparticles; pNIPAM: poly(N-isopropylacrylamide); NIR: Near Infrared radiation; PEG: 
poly(ethyleneglycol); PDT: Photodynamic theraphy; ROS: Reactive Oxigen Species; UV-
vis: Ultraviolet-Visible radiation. 
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conversion of NIR light to UV-vis light: 
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156, 157, 158, 159, 
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Temperature 
Conformational changes in polymers:  
pNIPAM and analogs [163, 164, 165, 
166] 
PEG acrylates [167] 
Disassembly of coiled coil motifs [168] 
   
Magnetic fields 
Increase of temperature under the action of an 
alternating magnetic field 
 
Superparamagnetic cores in core@MSNs: Fe3O4 
and Fe3O4/Fe cores 
[169, 170] 
IONPs in the silica network [171, 172, 173] 
IONPs as mesopore caps [174] 
   
Ultrasounds MSNs capping with a copolymer containing a 
labile acetal group which is cleaved upon US 
application. Change of polymer conformation 
[180, 181, 182] 
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due to hydrophobic to hydrophilic 
transformation. 
   
Multi-stimuli responsive MSNs 
Dual responsive MSNs 
pH or ATP concentration [184] 
pH or glucose concentration [185, 186, 187] 
Enzyme (hyaluronidase) and redox (GSH) [188] 
Sequential release of 
different sized cargos 
Electro-stimuli and UV irradiation [189] 
Use of dual responsive 
polymers 
cargo loading at 4 °C and conformation change 
at 37 °C: 
 
upon US irradiation [180] 
upon H2O2 stimulus [190] 
dual-responsive polymers as gatekeepers:  
pH and thermoresponsive [191] 
pH and visible light responsive [192] 
Combination of 
chemotherapy and PTD 
Drug release under acidic pH and 1O2 generation 
with NIR irradiation 
[193] 
1O2 generation upon 660 nm irradiation and 
gatekeeper cleaving by the generated 1O2 
[194] 
Three gated MSNs Redox, enzymatic hydrolysis and contact with 
cell membrane 
[195] 
   
 
Abbreviations: ATP: Adenosine triphosphate; GSH: Glutathione; IONPs: Iron oxide nanoparticles; 
pNIPAM: poly(N-isopropylacrylamide); NIR: Near Infrared radiation; PEG: poly(ethyleneglycol); 
PDT: Photodynamic theraphy; ROS: Reactive Oxigen Species; UV-vis: Ultraviolet-Visible 
radiation. 
 
 
